New Insights Into the Role of Equine Infectious Anemia Virus S2 Protein in Disease Expression by Covaleda Salas, Lina M.
  
NEW INSIGHTS INTO THE ROLE OF EQUINE INFECTIOUS ANEMIA 
VIRUS S2 PROTEIN IN DISEASE EXPRESSION 
 
 
A Dissertation 
by 
LINA MARIA COVALEDA SALAS  
 
 
Submitted to the Office of Graduate Studies of 
Texas A&M University 
in partial fulfillment of the requirements for the degree of  
 
DOCTOR OF PHILOSOPHY 
 
 
May 2010 
 
 
Major Subject: Veterinary Microbiology
 NEW INSIGHTS INTO THE ROLE OF EQUINE INFECTIOUS ANEMIA 
VIRUS S2 PROTEIN IN DISEASE EXPRESSION 
 
 
A Dissertation 
by 
LINA MARIA COVALEDA SALAS  
 
Submitted to the Office of Graduate Studies of 
Texas A&M University 
in partial fulfillment of the requirements for the degree of  
 
DOCTOR OF PHILOSOPHY 
 
Approved by: 
Chair of Committee,  Susan Payne 
Committee Members, Judith M. Ball 
 C. Jane Welsh 
 Van G. Wilson 
Head of Department, John R. August 
 
 
 
May 2010 
 
 
Major Subject: Veterinary Microbiology 
 iii 
ABSTRACT 
 
New Insights Into the Role of Equine Infectious Anemia Virus S2 Protein in Disease 
Expression. (May 2010) 
Lina Maria Covaleda Salas, B.S., Universidad de los Andes, Colombia 
Chair of Advisory Committee: Dr. Susan Payne 
 
Equine infectious anemia virus (EIAV) is an important animal model to study the 
contribution of macrophages in viral persistence during lentiviral infections. EIAV is 
unique amongst the lentiviruses in that it causes a rapid, rather than the very slow 
disease progression, characteristic of other lentiviral infections. The accessory gene, S2, 
unique to EIAV, is an important determinant in viral pathogenesis. A functional S2 gene 
is required to achieve high-titer viremia and the development of disease in infected 
horses. Despite its essential role, the mechanisms by which S2 influences EIAV 
pathogenesis remain elusive. The goal of this research was to gain insight into the role of 
S2 in pathogenesis. To accomplish this goal we: (i) Examined the effects of EIAV and 
its S2 protein in the regulation of the cytokine and chemokine responses in macrophages, 
(ii) Assessed the influence of EIAV infection and the effect of S2 on global gene 
expression in macrophages and (iii) Identified host cellular proteins that interact with S2 
as a starting point for the identification of host factors implicated in S2 function.  
 iv 
 The results from this study provide evidence for a role of S2 in enhancing a pro-
inflammatory cytokine and chemokine response in infected macrophages. Specifically, 
S2 enhances the expression of IL-1α, IL-1β, IL-8, MCP-2, MIP-1β, IP-10 and a newly 
discovered cytokine, IL-34. Involvement of S2 in cytokine and chemokine dysregulation 
may contribute to disease development by optimizing the host cell environment to 
promote viral dissemination and replication. Microarray analyses revealed an interesting 
set of differentially expressed genes upon EIAV infection. Genes affected by EIAV were 
involved in the immune response, transcription, translation, cell cycle and cell survival.   
Finally, we used the yeast two-hybrid system to identify S2 host cellular 
interacting proteins. We identified osteosarcoma amplified 9 (OS-9) and proteasome 26S 
ATPase subunit 3 (PSMC3) proteins as interacting partners of S2. Additional evidence is 
needed to demonstrate the physiological relevance of these interactions in vivo.  
In summary, the results from this study contribute towards our understanding of 
the role S2 in disease expression and allow the formulation of new hypotheses as to the 
potential mechanisms of action of S2 during EIAV infection.  
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CHAPTER I 
AN INTRODUCTION TO EQUINE INFECTIOUS ANEMIA VIRUS, THE 
DISEASE AND THE S2 PROTEIN 
 
History 
Equine Infectious Anemia (EIA), also known as “swamp fever”, is a worldwide 
infectious disease that affects members of equine family. Although the disease was first 
described in France in 1843, it was not until 1976 that the etiological agent, equine 
infectious anemia virus (EIAV) was classified as a retrovirus (Charman et al., 1976). In 
1978 it was classified within the subfamily Lentiviridae (Gonda et al., 1978).  EIAV has 
an important place in the history of retroviruses because it is the (i) first animal disease 
proven to be caused by a filterable agent (virus) in 1904, (ii) the first retrovirus 
confirmed to be transmitted by insects (deerflies and horseflies), (iii) the first retrovirus 
for which antigenic drift was described and (iv) the first retrovirus for which a diagnostic 
test was approved (Coggins et al., 1972; Kono et al., 1973; Stein, 1942; Vallée H., 
1904). The diagnostic test, approved in the 1970s, is an agar-gel immunodiffusion assay 
commonly known as the Coggins test developed to identify EIAV-infected carrier 
animals. Although other serologic and PCR based assays have been developed, the 
Coggins test is the international “gold standard” procedure for routine testing of EIA 
(Cook et al., 2002; Issel and Cook, 1993; Nagarajan and Simard, 2001). 
 
____________ 
This dissertation follows the style and format of Virology. 
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EIAV Transmission and Control 
The main route of EIAV transmission is through mechanical transfer of blood by 
blood-feeding insects such as horse and deer flies (Kemen et al., 1978). EIAV also can 
be spread by contaminated needles, through semen of an infected stallion or by in-utero 
passage from mare to foal (Kemen MJ Jr, 1972; Metcalf, 2001). Although there is no 
effective treatment or approved vaccine for EIA, the disease has been successfully 
managed in most countries by the establishment of mandatory measures to control the 
spread of disease (Issel et al., 1990). The regulations include: surveillance testing 
(Coggin’s test), mandatory reporting of positive EIAV carriers, life-long quarantine or 
destruction of infected animals and mandatory testing for imported horses. 
EIAV Structure, Genome Organization and Gene Expression 
EIAV virions exhibit the morphology and virion organization characteristic of 
other lentiviruses. As depicted in Fig. 1.1A, EIAV particles have a roughly spherical 
shape of about 100-200 nm in diameter partly covered by distinctive surface projections, 
which consist of two viral glycoproteins gp90 and gp45 (Nakajima et al., 1974). The 
matrix (M) protein lies underneath the viral envelope forming the inner shell, the capsid 
(CA) protein forms a conical core that surrounds the nuclecapsid (NC) which coats and 
protects the RNA genome. The genome consists of two identical copies of positive 
single-stranded RNA, each of which is associated with a molecule of cellular tRNALys3 
required as a primer for the initiation of reverse transcription (Arts et al., 1996).  
 
 3 
 
Figure 1.1. EIAV virion, genome organization and transcription map. (A) EIAV virion structure. (B) 
Schematic representation of the EIAV genome and transcripts. The 8.2 kb viral genome encodes the genes 
gag, pol, env, tat, rev and S2. The major EIAV mRNA transcripts are: (a) an unspliced transcript with a 
dual role as template for translation of the Gag and Gag-Pol polyproteins or as full-length RNA that is 
packaged into the virions (b) single spliced transcript that encodes the Tat, S2 and Env proteins, (c,d) 
multiply spliced mRNAs encoding both the Tat and Rev proteins, and (e) single spliced mRNA that 
encodes the Ttm protein. 
 
Among the lentiviruses, the EIAV genome is the smallest and genetically the 
simplest. The EIAV genome is 8.2 kb and contains only 6 genes that are classified into 
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three categories: structural, regulatory and accessory genes (Fig. 1.1B). The structural 
genes gag, pol and env, common to all retroviruses, are required for particle formation 
and replication. The regulatory genes S1 (tat) and S3 (rev) are essential for viral gene 
expression and replication both in vivo and in vitro (de Parseval and Elder, 1999; Miller 
et al., 2000). The accessory gene S2, whereas dispensable for viral replication in vitro, is 
necessary for robust viral replication and disease expression in vivo (Fagerness et al., 
2006; Li et al., 1998; Payne, 2006). Long terminal repeat (LTR) sequences present at 
both the 5’ and 3’ ends of the proviral genome are involved in controlling viral 
transcription thus are key players in cell tropism and virulence (Derse et al., 1987; Payne 
et al., 1999; Payne et al., 2004). 
Analyses using several EIAV-specific probes have identified at least 5 specific 
transcripts that share the same 5’ sequences (Maury, 1998). As seen in Fig. 1.1B, the 
major EIAV mRNA transcripts are: (a) the 8.2 kb unspliced transcript which can either 
serve as template for translation of Gag and Gag/Pol polyproteins or as genome-length 
RNA that is packaged into progeny virions, (b) the 3.5 kb, single spliced transcript that 
encode Tat, S2 and Env, (c,d) the ~ 2 kb, multiply spliced mRNAs that express Tat and 
Rev, and (e) the single spliced transcript that encodes the Ttm protein (Beisel et al., 
1993; Noiman et al., 1990; Schiltz et al., 1992).  
Lentiviruses have a distinctive pattern of gene expression that can be separated 
into early and late phases. Early gene expression is characterized by the appearance of 
multiply spliced transcripts encoding Tat and Rev proteins. Late gene expression 
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corresponds to unspliced or partially spliced mRNAs that code for Gag and Gag-Pol 
structural proteins and the accessory proteins S2 and Ttm (Clements and Zink, 1996).  
 EIAV transcription is regulated in a cell type and differentiation dependent 
manner by a complex interplay among cellular transcription factors, the virally encoded 
transactivator of transcription Tat and the EIAV LTRs (Maury, 1998). The U3 region in 
the LTR acts as a constitutive viral promoter and contains cis-acting DNA elements that 
are known to be binding sites for transcription factors such as MDBP, PEA2, Oct, CRE 
and PU.1 (Carvalho et al., 1993). Studies have shown that PU.1 binding sites in the LTR 
are critical for EIAV LTR expression in primary macrophages, while in fibroblastic cell 
lines the PEA2, Oct and CRE binding motifs are important (Hines et al., 2004; 
Lichtenstein et al., 1999; Maury et al., 2000) 
EIAV Proteins and Their Function 
Although the EIAV genome contains only 6 genes, it is capable of generating 14 
distinct proteins (Table 1.1) by alternative splicing, production of bicistronic mRNA, 
ribosomal frameshifting, ribosomal leaky scanning mechanisms and proteolytic 
processing (Carroll and Derse, 1993; Montelaro, 2003; Payne, 2006).  
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Table 1.1. EIAV structural and regulatory proteins 
Gene Protein Function 
gag CA (p26) 
MA (p15) 
NC (p11) 
p9 
 
Capsid protein 
Matrix protein 
Nucleocapsid protein 
Critical for virion release  
pol PR (p12) 
RT (p66/p51) 
DU (p15) 
IN 
 
Protease 
Reverse transcriptase/RNase H 
dUTPase 
Integrase 
 
env SU (gp90) 
TM (gp45) 
 
Surface unit protein 
Transmembrane protein 
 
S1 Tat 
 
Transcriptional transactivator 
 
S2 S2 
 
Virulence factor 
 
S3 Rev 
 
mRNA Splicing/nuclear export 
 Ttm Unknown 
  
 
The gag gene encodes the precursor polyprotein Pr55gag, which is proteolytically 
cleaved upon virion maturation by the viral-encoded protease (PR). The cleavage 
products from the N-terminus are matrix (MA) p15, capsid (CA) p26, nucleocapsid (NC) 
p11 and p9 (Hussain et al., 1988). The Gag precursor plays an essential role not only in 
the course of virus assembly but also during the budding process (Leroux et al., 2004). 
Even though the gag and pol genes are in different reading frames, in 
approximately 5% of Gag translation events, a Gag-Pol polyprotein is made by a -1 
ribosomal frameshifting (Chen and Montelaro, 2003). The pol gene is expressed as a 
Gag-Pol precursor protein (Pr180) that is also cleavage by the viral protease into the 
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mature Gag proteins and into the reverse transcriptase-RNaseH (RT-RNaseH) p66/p51, 
protease (PR) p12, integrase (IN) and a dUTPase. The EIAV dUTPase is required for 
productive viral replication in non-dividing cells such as macrophages (Le Grice et al., 
1991; Lichtenstein et al., 1995; Threadgill et al., 1993; Wohrl et al., 1994).  
The env gene, the most variable region of the EIAV genome encodes a 
glycosylated precursor polyprotein gp135 (Payne et al., 1987). Gp135 has both receptor-
binding and fusion activities and is processed by proteolytic cleavage to yield the mature 
surface glycoprotein gp90 (SU). SU is responsible for recognition of the cell surface 
receptor (ELR1) and gp45 (TM), a transmembrane protein is essential for membrane 
fusion (Rice et al., 1990; Sun et al., 2008).  
SU is a highly glycosylated and highly variable surface protein (Montelaro et al., 
1984). Since SU is a major target of the humoral immune response, these properties 
allow the virus to evade the immune response by escaping neutralizing antibody 
recognition (Howe et al., 2002). In fact, neutralizing antibodies are produced to regions 
that lie predominantly within the variable region in SU (Hussain et al., 1987). In addition 
to a role in immune evasion, studies have shown that SU is also a virulence determinant 
(Ball et al., 2005; Payne et al., 2004).  
In contrast to other lentiviruses, EIAV is unique in that the TM protein undergoes 
an additional carboxyl-terminal processing, which yields an N-terminal glycosylated 
32kDa (p32) and a non-glycosylated 20kDa (p20) proteins (Rice et al., 1990). Similar to 
SU, TM is also subject to genetic variation but is not as variable as the SU region 
(Leroux et al., 1997; Maury et al., 2005). 
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Tat is an 8 kDa regulatory protein, expressed early in the replication cycle and 
essential for optimal transactivation of viral gene expression and viral replication 
(Noiman et al., 1991). In the absence of Tat, most of the viral transcripts are prematurely 
released from the DNA template, leading to the accumulation of short transcripts and a 
substantial decrease in the production of fully elongated mRNAs (Maury et al., 1994; 
Selby et al., 1989). Similar to other known lentiviral Tat proteins, EIAV Tat has a 
modular structure containing separate RNA-binding and transcriptional activation 
domains (Derse and Newbold, 1993). Tat binds directly to an RNA stem-loop regulatory 
element designated TAR (trans-activation-responsive region) present at the 5’ end of all 
nascent viral mRNA transcripts and stimulates transcription elongation by recruitment of 
the positive transcription elongation factor b (P-TEFb) complex to the TAR element 
(Anand et al., 2008). P-TEFb recruitment is mediated by the specific interaction of Tat 
with the Cyclin T1 (CycT1) component of the P-TEFb complex, increasing the affinity 
of Tat for TAR (Bieniasz et al., 1999). Binding of CycT1 or P-TEFb to TAR does not 
occur in the absence of Tat (Jing Zhang, 2000). After binding to TAR, Tat induces the 
kinase activity of the second P-TEFb component, CDK9, a cyclin-dependent kinase to 
hyperphosphorylate the C-terminal domain (CTD) of RNA polymerase II (Pol II) (Taube 
et al., 2000). Hyperphosphorylation of Pol II increases its processivity, thus leading to 
enhanced efficiency of transcriptional elongation of the nascent viral mRNA (Karn, 
1999). Tat mediated transactivation increases viral transcription by greater that 100-fold 
(Garber et al., 1998). Analysis of EIAV Tat associated cellular proteins revealed the 
presence of at least three unidentified proteins involved in Tat transactivation in addition 
 9 
of the known CycT1, CDK9 and SF1 (Tat associated cofactor), suggesting there are 
additional factors that modulate EIAV Tat activity (Sune et al., 2000). 
Rev is the second regulatory protein essential for lentiviral gene expression and 
hence, for viral replication. Similar to Tat, Rev is encoded by a fully spliced transcript 
and is produced early during the viral replication cycle. EIAV Rev not only functions at 
the posttranscriptional level by mediating the nuclear export of unspliced and 
incompletely spliced viral mRNA, but also plays a key role in alternative splicing and 
viral mRNA stability (Belshan et al., 2000; Martarano et al., 1994). Rev function is 
critical for the switch in viral gene expression from the early regulatory phase to the late 
structural phase (Huffman et al., 1999). Since export of cellular mRNAs is tightly 
controlled by regulating nuclear exit of only fully spliced mRNAs, this poses a problem 
for lentiviruses that require export of both unspliced and partially spliced viral mRNA 
from the nucleus to the cytoplasm to serve as template for translation of the structural 
proteins, S2 and Ttm or to serve as the viral genome (Cullen, 2000). Lentiviruses 
overcome this limitation by the expression of Rev, the presence of a Rev-responsive 
element (RRE) within the viral pre-mRNA and the hijacking of cellular mRNA export 
adaptors (Sandri-Goldin, 2004). The EIAV Rev protein harbors a nuclear localization 
signal (NLS), a leucine-rich nuclear export signal (NES) and an RNA-binding domain 
composed of two short discontinuous motifs (Ihm et al., 2009; Lee et al., 2006). Both the 
NLS and NES domains are essential for Rev function allowing it not only to shuttle in 
and out of the nucleus but also for the specific interaction with RRE (Stauber et al., 
1998). Briefly, the sequential steps involved in Rev- mediated nuclear export are: (a) 
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binding to the RRE, a specific sequence present in all unspliced and partially spliced 
viral pre-mRNAs, (b) Rev multimerization, (c) formation of a nuclear export 
ribonucleoprotein complex composed of Rev-RRE, cellular nuclear export factor 
(CRM1) and RanGTP, which targets viral mRNA for nuclear export, (d) cargo release in 
the cytoplasm and (e) Rev recycling whereby Rev is imported back into the nucleus to 
interact with newly transcribed viral pre-mRNAs (Askjaer et al., 1998; Otero et al., 
1998). 
S2 is unique to EIAV and does not display significant sequence homology with 
any other retroviral or cellular protein. S2 gene is located in the pol-env intergenic region 
and encodes a small 65 amino acid, 7 kDa protein. S2 is synthesized at a late phase of 
the viral life cycle by a leaky ribosome scanning mechanism from either a singly spliced 
tricistronic mRNA encoding Tat, S2 and Env or from bicistronic mRNA encoding S2 
and Env (Carroll and Derse, 1993; Schiltz et al., 1992). Immunolocalization studies 
suggest that S2 is mainly localized to the cytoplasm with a punctuate pattern towards the 
perinuclear region. In the same study S2 was found to directly interact with the EIAV 
Gag precursor in vitro, suggesting a role in viral particle assembly, however S2 does not 
appear to be incorporated into the EIAV particles (Yoon et al., 2000). Antibodies against 
S2 can be detected in sera from EIAV infected horses indicating that it can elicit a 
humoral immune response (Schiltz et al., 1992).  
Examination of S2 viral sequences from natural or experimentally infected 
horses during persistent infection reveals a high level of conservation, indicating that S2 
plays an important functional role during natural infection (Craigo et al., 2009; Leroux et 
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al., 2004; Li et al., 2000). As seen in Fig. 1.2, amino acid sequence alignments of 
available S2 proteins indicate several putatively conserved, well-characterized protein 
motifs and therefore are presumed to play an important role in S2 function in vivo: an N-
terminal myristoylation motif (GVTWSA), the nucleoporin motif (GLFG), the nuclear 
localization signal (RRKQETKK) motif, the proline rich (PxxP) SH3 binding motif, a 
casein kinase II (CKII) phosphorylation motif and at least two protein kinase 
phosphorylation sites (Leroux et al., 2004; Li et al., 2000). However, is important to note 
that the PxxP motif has recently been found to be absent (substitution of the first proline 
(P) to leucine (L) from a recently characterized virulent field isolate (EIAVPA) (Craigo et 
al., 2009). Analysis of S2 sequences from additional virulent field strains is warranted. 
 
 
Figure 1.2. Alignment of published EIAV S2 amino acid sequences. The labels to the left indicate the 
virus isolate designation. The Consensus line shows the amino acid present in the majority of isolates at 
each position. Below the consensus identity sequence the dark green color indicates that the residue is the 
same across all sequences, light green indicates less than complete identity and red, very low or no 
identity. Dashes are use to indicate amino acid deletions in the alignment. Several putative motifs are 
indicated. Nucleoporin motif, N-terminal myristoylation site, caseine kinase II phosphorylation site, 
(PXXP) SH3-binding motif, protein kinase C phosphorylation site and the nuclear localization signal. 
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EIAV Cell Tropism  
The identification of macrophages as the predominant cellular targets of EIAV in 
the natural host came from analysis of tissues from acutely infected horses by direct 
immunofluoresence and in-situ hybridization (McGuire et al., 1971; Sellon et al., 1992). 
During acute or asymptomatic infection viral DNA and RNA are predominantly detected 
in mature tissue macrophages of the liver, lymph nodes, kidney, bone marrow and the 
spleen. The spleen is estimated to contribute to over 90% of the tissue viral burden 
during acute disease (Harrold et al., 2000; Oaks et al., 1998). In addition, viral RNA has 
been detected in endothelial cells suggesting that these cells can harbor the virus, but 
their role or contribution to pathogenesis is unknown (Oaks et al., 1999).  Peripheral 
blood monocytes are susceptible to viral infection but differentiation of monocytes into 
macrophages is a prerequisite step for active replication (Maury, 1994; Sellon et al., 
1992; Sellon et al., 1996). Even though EIAV-infected monocytes do not support 
productive infection, they may serve not only as a vehicle for viral dissemination to 
macrophage rich target organs but they also can act as reservoirs for the virus.  
In vitro, both wild-type and cell-adapted EIAV strains can replicate in equine 
monocyte-derived macrophages and tissue macrophage derived from the spleen or bone 
marrow (Raabe et al., 1998b). In addition, some wild-type isolates of EIAV have been 
adapted to growth in equine dermis (ED), fetal equine kidney (FEK), feline embryonic 
fibroblast (FEA), canine D17 osteosarcoma and canine macrophage-like (DH82) cell 
lines (Bouillant et al., 1986; Carpenter and Chesebro, 1989; Hines and Maury, 2001; 
Klevjer-Anderson et al., 1979).  However, attenuation of wild-type strains has been 
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reported to occur after repeated passage in cell culture although some strains have been 
shown to revert to a fully virulent phenotype after serial passages in horses (Carpenter 
and Chesebro, 1989; Orrego et al., 1982). Recently, an equine macrophage-like cell line 
that supports propagation of a virulent EIAV strain was characterized (Fidalgo-Carvalho 
et al., 2009).  
Clinical Course of EIAV Infection 
Natural or experimental infection of horses with EIAV causes a rapid rather than 
a very slow disease progression characteristic of most lentiviral infections (Cheevers and 
McGuire, 1985). As seen in Fig. 1.3, the clinical course of EIAV infection is divided 
into three distinct stages: acute, chronic and inapparent. The symptoms associated with 
acute disease usually occur within one to four weeks after infection and are of short 
duration. Symptoms of acute EIA include fever, depression, rapid weight loss, anemia, 
thrombocytopenia, and high levels of viremia (Russell et al., 1999).  
Some infections progress to chronic EIA, in which infected animals develop 
recurrent cycles of fever, associated with high viral load and clinical signs similar to the 
acute phase (McGuire et al., 1990; Sellon, 1993). Recurrences appear during an interval 
of 6 to 8 months and are interspersed with normal clinical periods (weeks or months). 
Approximately 8 to 12 months postinfection more than 90% of infected horses progress 
to a life-long inapparent carrier stage characterized by very low viral loads and lack of 
clinical signs (Li et al., 2003; Sellon et al., 1994). The inapparent carrier stage seems to 
be associated with the establishment of a strict immunological control over virus 
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replication. Inapparent carriers are a constant source of transmission to uninfected horses 
(Hammond et al., 2000; Issel et al., 1982). 
 
 
Figure 1.3. Clinical course of EIAV infection (adapted from Leroux et al. 2004).  
 
Cellular, Humoral and Cytokine Responses during EIAV Infection 
The success of EIAV persistence is linked to its overall ability to evade the host 
antiviral defenses by the generation of antigenic variants (quasispecies), which arise 
mainly through mutation of the env gene (Howe et al., 2002; Leroux et al., 1997; 
Lichtenstein et al., 1996; Montelaro et al., 1984). Each recurrent viremic episode during 
EIAV infection (chronic phase) is associated with the appearance of antigenic variants 
(Zheng et al., 1997). The initial humoral response is characterized by a high titer of low 
avidity antibodies (i.e., poor neutralizing activity). Emergence of quasispecies in 
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infected animals leads to a delayed production of neutralizing antibodies (6 to 8 months). 
EIAV-specific cytotoxic T-lymphocytes (CTL) appear within 3 to 4 weeks post-
infection and are associated with the resolution of initial viremia (McGuire et al., 2002; 
Oaks et al., 1998). The inapparent phase is characterized by the presence of high avidity 
antibodies (i.e., effective neutralizing activity) and high levels of CTL activity to EIAV 
Gag and Env proteins. Therefore, suppression of viral replication and disease during the 
inapparent stage of EIAV infection is associated with strong CTL and neutralizing 
antibody responses (McGuire et al., 2004). 
A main feature during lentiviral infection is the dysregulation of the cytokines 
and chemokines with resulting detrimental effects on the host immune response. During 
the course of HIV, SIV, and FIV infections, cytokines are known to modulate viral 
replication, persistence and disease progression in the host. In contrast, the dynamics of 
the cytokine/chemokine responses during the course of EIAV infection have not been 
fully determined. It has been shown that early during infection (0.5-1 h post-infection) 
there is a pro- and anti-inflammatory response to EIAV infection in vitro. eMDMs 
infected with EIAV17 display significantly increased expression of interleukin 1 alpha 
(IL-1α), interleukin 1 beta (IL-1β), interleukin 6 (IL-6), interleukin 10 (IL-10) and tumor 
necrosis factor alpha (TNF-α) early during infection (0.5-1 h post-infection) suggesting 
a role of these pro-inflammatory cytokines during the initial response to EIAV infection 
(Lim et al., 2005). Some studies have reported that during EIAV infection, serum levels 
of TNF-alpha, transforming growth factor beta (TGF-β) and interferon alpha (IFN-α) are 
significantly increased and might be associated with the development of 
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thrombocytopenia in EIAV-infected foals (Tornquist et al., 1997). In addition, increased 
levels of pro-inflammatory cytokines such as IL-6 and TNF-α are found in the serum of 
infected ponies and are associated with high levels of viremia (Tornquist et al., 1997).  
Changes in cytokine and chemokine levels during the course of EIAV infection 
could have a major impact in the immune system and may influence pathogenesis by 
enhancing or suppressing EIAV replication as well as favoring the formation of virus 
reservoirs.  
EIAV S2 Is a Virulence Factor 
Although its mode of action is not understood, studies have shown that S2 is 
essential for maintenance of high viral load and disease expression in the Shetland pony 
model (Fagerness et al., 2006; Li et al., 2000). The functional role of S2 in EIAV 
replication was formally assessed in vitro by infecting either EIAV permissive cell lines 
or primary equine monocyte-derived-macrophages (eMDM) with wild-type or S2 mutant 
proviruses. In these assays, S2 was found to be largely dispensable for viral replication 
in vitro, although its presence may confer a slight growth advantage (Fagerness et al., 
2006; Li et al., 1998). 
In contrast to the results in vitro, the biological importance of S2 in EIAV 
infection came from two different in vivo studies using the Shetland pony model. In the 
first study (Li et al., 2000), ponies were infected with either EIAVUK, a cell adapted 
virulent molecular clone or EIAVUK lacking S2. Ponies infected with EIAVUK, 
experienced a reduction in platelet count compared with ponies infected with the S2-
deleted virus, although this was not considered to be clinically relevant. Moreover, 
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plasma RNA levels were significantly greater in ponies infected with the parental virus 
compared with the S2-deleted virus, suggesting a role of S2 in viral replication in vivo. 
However, in this study, ponies infected with the EIAVUK virus failed to develop the 
characteristic clinical signs of EIAV infection such as febrile episodes and 
thrombocytopenia, making it hard to judge the importance of S2 in disease expression. 
In the second study by Fagerness et al. (2006) ponies infected with EIAV17, a 
highly virulent molecular clone, displayed the typical signs of EIA disease, including 
key features such as: febrile episodes, thrombocytopenia, and high levels of viremia. In 
contrast, ponies infected with an S2-deleted virus (EIAV17ΔS2) display a decreased viral 
load and failed to develop any clinical signs of the disease (Fig. 1.4). Taken together, 
these studies reveal a role for S2 not only for enhancement of viral replication in the 
infected animal, but also for the development of disease.  
Finally, amino acid sequence comparison between the EIAV Japanese virulent 
strain V70 and the attenuated strain V26 reveals that the initiation codon of S2 is absent 
in the attenuated virus, likely abolishing the expression of S2. In vitro, V26, replicates at 
high levels but when is used in in vivo experiments exhibits a marked reduction in 
replication, suggesting that S2 is a key determinant of viral replication and pathogenicity 
in vivo (Zheng et al., 2000). 
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Figure 1.4. Clinical profiles of ponies infected with (A) EIAV17 or (B) EIAV17ΔS2. Rectal temperature 
(); Platelets (). Figure courtesy of Dr Susan Payne, Texas A&M University. 
 
EIAV Vaccines 
After more than three decades since its classification as a retrovirus, there is still 
not an U.S. Food and Drug Administration-approved vaccine or treatment for EIAV. 
Several attempts have been made to develop a safe and effective EIAV vaccine, but have 
not been successful. However, these studies have been important in understanding the 
interaction between the immune response and vaccine candidates, which is key to 
developing an effective EIAV vaccine. 
Different vaccine design strategies have been tested. The first vaccine against 
EIAV, known as the donkey leukocyte-attenuated vaccine (DLV), was developed and 
has been used in China since the late 1970s. This vaccine was generated by serial 
passages of the LN40 field isolate first in donkeys and then in vitro in primary donkey 
macrophages (Shen, 1985; Shen et al., 2006). Although the researchers have reported 
that the vaccine protects horses and donkeys against EIAV infection and is stable and 
safe for animal use (Wei et al., 2009; Zhang et al., 2007), this vaccine is not acceptable 
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in most of the countries worldwide. There is the potential risk of this vaccine reverting to 
virulence, and as would be expected, vaccinated horses will have a positive Coggin’s 
test, making it impossible to distinguish between vaccinated and EIAV infected animals.  
 An EIAV whole-virus inactivated vaccine and a viral envelope glycoprotein-
based subunit vaccine developed by Issel et al. (1992) protected vaccinated ponies after 
challenge with the homologous EIAV strain but failed to protect them after challenge 
with a virulent heterologous EIAV strain (EIAVPV). In addition, the subunit vaccine had 
the capability to enhance the disease after challenge with the EIAVPV strain (Issel et al., 
1992). Similar results were obtained in animal trials using a baculovirus-expressed 
recombinant vaccine (rgp90), developed by Wang et al. (1994), where the vaccine failed 
to protect immunized ponies from infection after challenge with the virulent EIAVPV 
strain. Moreover, a wide range of clinical signs, from marked exacerbation to no 
symptoms of the disease, were observed in the vaccinated ponies (Raabe et al., 1998a; 
Wang et al., 1994). Although it was hypothesized that the antibody response could be 
responsible for vaccine-induced enhancement of the disease, the authors did not find an 
association between antibody levels and the exacerbation of the disease.  
 Recently, an EIAV SU codon-optimized vaccine was also evaluated for its ability 
to elicit immune responses in immunized ponies (Cook et al., 2005). Immunized ponies 
were able to elicit a specific humoral and cellular response after immunization with the 
codon-optimized SU vaccine but similar to the other vaccines, the generated immune 
response failed to confer effective protection against challenge with EIAVPV.  
 One of the most successful vaccine trials reported was the use of a live attenuated 
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EIAV proviral vaccine were the S2 gene is mutated (EIAVUKΔS2) (Li et al., 2003). As 
mentioned before, absence of S2 has been shown to severely reduce viral replication and 
disease expression in vivo (Fagerness et al., 2006; Li et al., 2000). When used to infect 
ponies, this vaccine provided protection from infection after challenge with the virulent 
strain EIAVPV. Protection was correlated with the development of both mature Env-
specific cellular and humoral responses. Additional trials need to be conducted using 
different EIAV field isolates to determine if the immune response elicited by this 
vaccine is able to confer protection against other known EIAV strains. 
Significance and Goals of the Study 
EIAV serves a valuable animal model not only as a macrophage-tropic lentivirus, 
but also as a model for host immune control to lentiviral infection. Although S2 has been 
recognized to play an important role in disease expression since the early 2000’s, its 
mechanism(s) of action are not clearly elucidated. The primary goals of this work were 
(i) To examine the effects of EIAV and its S2 protein in the regulation of the cytokine 
and chemokine responses in primary macrophages at different time points post-infection, 
(ii) To assess the influence of EIAV infection and the effect of S2 on gene expression in 
primary macrophages and (iii) To identify host cellular proteins that interact with S2 and 
could act as mediators of S2 function. 
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CHAPTER II 
EIAV S2 ENHANCES PRO-INFLAMMATORY CYTOKINE AND 
CHEMOKINE RESPONSE IN INFECTED MACROPHAGES  
 
Overview 
Equine infectious anemia virus (EIAV) infection is distinctive in that it causes a 
rapid onset of clinical disease relative to other retroviruses. In order to understand the 
interaction dynamics between EIAV and the host immune response, we explored the 
effects of EIAV and its S2 protein in the regulation of the cytokine and chemokine 
response in macrophages. EIAV infection markedly altered the expression pattern of a 
variety of pro-inflammatory cytokines and chemokines monitored in the study. 
Comparative studies in the cytokine response between EIAV17 and EIAV17ΔS2 infection 
revealed that S2 enhances the expression of IL-1α, IL-1β, IL-8, MCP-2, MIP-1β and IP-
10. Moreover, S2 specifically induced the expression of the newly discovered cytokine, 
IL-34. Taken together, these results may help explain the effect of cytokine and 
chemokine dysregulation in EIAV pathogenesis and suggest a role of S2 in optimizing 
the host cell environment to promote viral dissemination and replication.  
 
 
 
____________ 
Reprinted with permission from “EIAV S2 enhances pro-inflammatory cytokine and 
chemokine response in infected macrophages” by Covaleda, L., Fuller, F.J., and Payne, 
S.L., 2010. Virology 397 (1), 217-223. Copyright 2010 by Elsevier. 
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Introduction 
Equine Infectious Anemia (EIA), commonly known as swamp fever, is a 
worldwide disease of equids. The causative agent of EIA is equine infectious anemia 
virus, or EIAV (genus lentivirus, family Retroviridae), closely related to human 
immunodeficiency virus (HIV). EIAV is transmitted primarily through biting flies, such 
as the blood-feeding horseflies and deerflies (Foil and Issel, 1991). Natural or 
experimental infection of horses with EIAV causes a rapid, rather than the very slow 
disease progression that is characteristic of most lentiviral infections (Cheevers and 
McGuire, 1985).  
The clinical course of EIAV infection is divided into three distinct stages: acute, 
chronic and inapparent. The symptoms associated with acute disease usually occur 
within one to four weeks after infection and are of short duration. Symptoms of acute 
EIA include fever, depression, rapid weight loss, anemia, thrombocytopenia, and high 
levels of viremia (Oaks et al., 1998; Russell et al., 1999). Some infections progress to 
chronic EIA, in which infected animals develop recurrent cycles of fever, associated 
with high viral load and clinical signs similar to the acute phase (McGuire et al., 1990; 
Sellon, 1993). Recurrences appear during an interval of 6 to 8 months and are 
interspersed with normal clinical periods (weeks or months).  
Approximately 8 to 12 months post-infection, more than 90% of infected horses 
progress to a life-long inapparent carrier stage characterized by very low viral loads and 
lack of clinical signs (Li et al., 2003; Sellon et al., 1994). The inapparent carrier stage 
seems to be associated with the establishment of strict immunological control over virus 
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replication. Inapparent carriers are a constant source of transmission to uninfected horses 
(Hammond et al., 2000; Issel et al., 1982). 
In addition to encoding the gag, pol and env genes common to all retroviruses, 
EIAV encodes a dUTPase in the pol gene that is required for productive viral replication 
in non-dividing cells such as macrophages (Lichtenstein et al., 1995; Threadgill et al., 
1993). EIAV also encodes four regulatory/accessory proteins: Tat, Rev, Ttm and S2. The 
S2 gene, located in the pol-env intergenic region encodes a 65 amino acid 7 kDa protein, 
which is synthesized in the late phase of the viral life cycle (Carroll and Derse, 1993; 
Schiltz et al., 1992). S2 is mainly localized in the cytoplasm and may interact with the 
EIAV Gag precursor in cell culture (Yoon et al., 2000). The S2 open reading frame is 
highly conserved, being found in all published EIAV sequences, indicating that it carries 
out a vital function in vivo (Leroux et al., 2004; Li et al., 2000). In vitro, S2 is not 
required for viral replication in cultured equine monocyte derived macrophages 
(eMDM), the natural target for EIAV replication (Li et al., 1998). However, the 
biological importance of S2 in viral pathogenesis has been demonstrated by 
experimental infection in Shetland ponies (Fagerness et al., 2006; Li et al., 2000). Ponies 
infected with a virus derived from the highly virulent molecular clone, EIAV17, 
experience severe febrile episodes accompanied by a significant decrease in platelet 
count and an increase in viral load, similar to those seen in natural infection. In contrast, 
ponies infected with a highly virulent molecular clone lacking a functional S2 protein 
(EIAV17ΔS2) display a decrease in viral replication and fail to develop any clinical signs 
of disease (Fagerness et al., 2006). Despite its essential role, the mechanisms by which 
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S2 influences EIAV pathogenesis are not understood. Since S2 does not display 
significant sequence homology with any other retroviral or cellular proteins, it has been 
difficult to predict its mode of action.  
Macrophages are considered the predominant cell type for EIAV infection. It has 
been shown that blood monocytes are permissive for EIAV, but differentiation of 
monocytes into macrophages is a prerequisite step for EIAV replication (Maury, 1994; 
Schiltz et al., 1992; Sellon et al., 1996). In addition to the role as reservoirs, infected 
monocytes may serve as vehicles capable of disseminating the virus to macrophage-rich 
organs such as the spleen, liver and kidney, which are the primary sites associated with 
high levels of EIAV replication in persistently infected horses (Oaks et al., 1998). Cells 
of the monocyte/macrophage lineage play an important role in the immune response 
against pathogens; these cells produce soluble factors such as cytokines and chemokines, 
which can orchestrate the immune response to infection.  
During EIAV infection, serum levels of tumor necrosis factor alpha (TNF-α), 
transforming growth factor beta (TGF-β) and interferon alpha (IFN-α) which can act as 
negative regulators of platelet production are increased before the clinical onset of 
thrombocytopenia (Tornquist et al., 1997). In addition, eMDMs infected with EIAV17 
displayed significantly increased expression of interleukin-1 (IL-1) α, IL-1 β, IL-6, IL-
10 and TNF-α early during infection (0.5-1 h post-infection) suggesting a role of these 
pro-inflammatory cytokines during the initial response to EIAV infection (Lim et al., 
2005). To examine the underlying immune mechanisms in the pathogenesis of EIAV and 
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the role, if any, of S2 in modulating this response, we studied the expression profiles of 
cytokines/chemokines over time in response to EIAV infection in eMDMs. 
EIAV serves a valuable animal model not only as a macrophage-tropic lentivirus, 
but also as a model for host immune control of lentiviral infection. Although S2 is not 
the sole virulence determinant for EIAV, elucidating the specific role(s) of S2 in disease 
expression will advance our understanding of the patho-mechanism of lentiviral 
infection. 
Materials and Methods 
Monocyte-derived macrophage cell culture 
Whole blood was collected from six adult EIA-negative healthy horses and 
centrifuged at 2100 rpm for 30 min to separate the buffy coat, which was then diluted 
1:3 with Hank’s balance salt solution (HBBS) containing 2 mM EDTA. Fifteen ml of 
endotoxin-free Histopaque-1077 (Sigma-Aldrich) was slowly layered underneath 20 ml 
of diluted buffy coat and centrifuged at 2100 rpm for 30 min at room temperature. 
Peripheral blood mononuclear cells (PBMCs) were harvested from the interface and 
washed by centrifugation at 1000 rpm for 10 min at 4 °C in cold entodoxin-free 
Alsever’s solution (0.1M D-glucose, 0.027 M sodium citrate, 0.002 M citric acid, 0.07 
M sodium chloride, pH 6.1) containing 1% penicillin-streptomycin, to remove platelets. 
Residual erythrocytes were lysed by incubation with 5 ml ACK lysis buffer (Invitrogen) 
for 3 min at 37 °C.  After washing three times with 50 ml Alsever’s solution, PBMCs 
were resuspended in RPMI 1640 medium supplemented with 10% heat-inactivated horse 
serum, penicillin (100 IU/ml), streptomycin (100µg/ml), and L-glutamine (2 mM). For 
 26 
monocyte isolation by plastic adherence, 12 x 106 PBMC per well were seeded into 12-
well plates (BD Falcon) and allowed to adhere overnight in a 37 °C humidified 5% CO2 
incubator. Nonadherent cells were removed by gently washing the plates, twice, with 
prewarmed RPMI complete media and the remaining adherent monocyte-enriched cells 
were allowed to differentiate for a further 48 h before infection. All reagents were 
screened and found negative for endotoxin and mycoplasma contamination using the 
Limulus Amebocyte lysate kit (Associates of Cape Cod) and MycoFind Kit (Clongen 
laboratories) respectively. 
Virus preparations 
Virus stocks were generated as previously described (Lim et al., 2005). Briefly, 
D17 cells were transfected with 10 µg of the molecular clones EIAV17 or EIAV17ΔS2 
plasmids by using the calcium phosphate method and virus particles harvested 72 h post-
transfection were used to infected eMDMs. Culture supernatants collected from 7 to 15 
dpi, were removed from infected eMDMs and cleared of cell debris by low-spin 
centrifugation. Virus stocks were assayed for RT activity as a measure of virus 
replication. Virus stocks were purified and concentrated via ultrafiltration using a 
Vivaflow 200 tangential flow system with a 100 kDa MWCO filter (Sartorius). After 
ultrafiltration, maintenance of virus infectivity was confirmed by growth in eMDMs and 
RT activity. No detectable levels of endotoxin were present in the purified virus stocks. 
Viral infectious titers were determined by the Reed-Muench formula after infecting 
eMDMs with 10-fold serial dilutions of the virus in sextuplicates and maintaining the 
culture for two weeks. 
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Infection of eMDM 
Three days post-plating, eMDM were mock infected (with cell culture media 
used to grow the cells), infected with EAIV17 or EIAV17ΔS2 at a multiplicity of infection 
(MOI) of 3 to achieve a near synchronous infection. Supernatants and cell extracts were 
collected from day 1 to 4 post-infection. Virus replication was monitored for RT activity, 
cytopathic effect (CPE) and viral mRNA transcription in samples collected at various 
time points post-infection. 
RNA isolation and cDNA synthesis 
At each time point (1-4 dpi), cells were harvested in RLT buffer (QIAGEN) and 
cell pellets were stored at -80 °C until ready for RNA isolation. Total RNA was isolated 
using the RNeasy kit from Qiagen, including DNaseI digestion according to 
manufacturer’s instructions. RNA was further assessed for quality and concentration 
using the Nano 6000 assay on the Agilent 2100 Bioanalyzer. cDNA was synthesized 
using the SuperScript Vilo cDNA Synthesis Kit (Invitrogen).  
Real time PCR 
TaqMan and SYBR Green based assays were used to analyze gene expression 
levels of 12 selected cytokine/chemokine target genes (Table 2.1). TaqMan real time 
PCR reactions were performed in a 10 µl total volume containing 0.5 µl of cDNA, 5 µl 
of EXPRESS qPCR SuperMix with premixed ROX (Invitrogen), 0.5µl of fluorescent 
primer/probe mix, and 4 µl of DEPC-treated water.  
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Table 2.1. Sequence of TaqMan primer/probe sets and SYBR Green primers* 
 
Gene  
Gene ID # Primer/probe Sequence 5’→3’ Product length (bp) 
IL-1α  100064969 Forward 
Reverse 
Probe 
 
CAATATCTTGCGACTGCTGCATTAA 
CTCTTCTGATGTATAAGCACCCATGT 
FAM-ACGCAGTGAAATTT-NFQ 
78 
IL-1β  100034237 Forward 
Reverse 
Probe 
 
TGTACCTGTCTTGTGGGATGAAAG 
GCTTTTCCATTTTCCTCTTTGGGTAA 
FAM-CCTACAGCTGGAGACAGT-NFQ 
93 
IL-6  100034196 Forward 
Reverse 
Probe 
 
GAAAAAGACGGATGCTTCCAATCTG 
TCCGAAAGACCAGTGGTGATTTT 
FAM-CAGGTCTCCTGATTGAAC-NFQ 
 
74 
IL-8  100037400 Forward 
Reverse 
Probe 
 
GCCACACTGCGAAAACTCA 
GCACAATAATCTGCACCCACTTTG 
FAM-ACGAGCTTTACAATGATTTC-NFQ 
95 
TNF-α  100033834 Forward 
Reverse 
Probe 
TTCTCGAACCCCAAGTGACAAG 
GCTGCCCCTCGGCTT 
FAM-ATGTTGTAGCAAACCC-NFQ 
65 
 
MCP-1  
 
 
100034136 
 
Forward 
Reverse 
Probe 
 
 
GCGGCCGCCTTCAG 
GCAGCAGGTGACTGGAGAAT 
FAM-CTCAGCCAGATGCAATTA-NFQ 
 
66 
MCP-2  100033950 Forward 
Reverse 
Probe 
 
TCACCAGCAGCCAGTGTTC 
GCACAGATCTCCTTGTCCACTTT 
FAM-AAGCTGTGATCTTCAAGACC-NFQ 
67 
MIP-1α  100057909 Forward 
Reverse 
Probe 
 
TCTGCAGCCAGGTCTTCTCT 
GAGAAGCAGCAGGCAGTTG 
FAM-TCGGCACCGAATGGTA-NFQ 
61 
MIP-1β  100057859 Forward 
Reverse 
Probe 
 
GCTGGTGGCTGCCTTCTG 
CGCAGGGTGTAAGAGAAGCA 
FAM-CAGCACCAATGGGCTCA-NFQ 
87 
IP-10  100050993 Forward 
Reverse 
Probe 
 
CAGAGTCCAAGACCGTCAAGAATTT 
GCCATCCGTATCAGTAGTACCGTAATT 
FAM-CAAAGGTCTAAAAGATCTCC-NFQ 
111 
18S  AJ311673 Forward 
Reverse 
Probe 
AAACGGCTACCACATCCAA 
TCGGGAGTGGGTAATTTGC 
FAM-AAGGCAGCAGGCGC-NFQ 
 
54 
IL-34* 
 
IL-10* 
100054703 
 
100034187 
Forward 
Reverse 
 
Forward 
Reverse 
 
TGCCCTTGCTGTAAACATAGC  
CCACACACTGTGATGATGAGG 
 
GGCAGTGGAGCAGGTGAAGA 
GATGTCAAACTCACTCATGGCTTT 
100 
 
 
79 
 
 
18S* 
 
Beta-actin* 
AJ311673 
 
100033878 
Forward 
Reverse 
 
Forward 
Reverse 
CACATCCAAGGAAGGCAGCA  
TTTTCGTCACTACCTCCCCGG 
 
TCACGGAGCGTGGCTACAG 
CCTTGATGTCACGCACGATTT 
66 
 
                63 
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SYBR Green real time PCR reactions contained 5 µl of SYBR GreenERTM qPCR with 
premixed ROX (Invitrogen), 200 nM of the primer mix, and DEPC-treated water. 
Amplification was carried out using the following parameters: 50 °C for 2 min, 95 °C for 
10 min, followed by 40 cycles of 95 °C for 15 s and by 60 °C for 30 s. A dissociation 
stage was included for SYBR Green real time PCR to confirm the amplification of a 
single product. All RT reactions, including no-template controls, were run in triplicate 
on an ABI 7900HT real-time PCR system. Data were collected and analyzed with the 
SDS 2.3 software. 
Data analysis and validation of chemokines TaqMan probes 
The Pfaffl method (Pfaffl, 2001) was used to calculate relative fold changes in 
cytokine/chemokine gene expression between mock-infected and infected samples. Data 
were first normalized to the endogenous control 18S rRNA or beta-actin and the mock-
infected samples from each time point were used as the calibrator control. TaqMan 
primer/probe sets for IL-1α, IL-1β, IL-6, IL-8, TNF-α and18S have been previously 
described and validated (Allen et al., 2007). TaqMan primer/probe sets for MCP-1, 
MCP-2, MIP-1α, MIP-1β, and IP-10, were obtained from Applied Biosystems. TaqMan 
probes and primers for SYBR Green real time PCR were designed to span at least one 
exon-exon junction to prevent amplification of genomic sequences. TaqMan probes were 
5’ labeled with 6-carboxyfluorescein (FAM) and 3’ with a nonfluorescent quencher 
(NFQ). RT-PCR products were separated by 2% agarose gel electrophoresis to confirm 
product size and specificity of each primer/probe set. Fragments were also analyzed by 
sequence to validate the identity of the PCR products. PCR efficiency from each 
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primer/probe set was determined by performing a 6-log dilution range from 3 different 
cDNA samples. Each dilution was run in triplicate. 
Viral RNA expression 
SYBR Green real time PCR was used to detect viral transcripts with specific 
primers (forward 5’-CGGGACAGCAGAGGAGAACT-3’ and reverse 5’-CAATCC 
CTAGAGACCTCAGGAAACAC-3’) spanning the splice site used to generate the 
single spliced, tricistronic mRNA that encodes Tat, S2 and Env. In addition, specific 
primers bearing the S2 mutation (forward 5’-AACACAGGAGGACAGGAAGCA-3’ 
and reverse 5’- TTACCCCTTTACCAAATACTCCCATA-3’) were used to screen for 
contamination with wild-type sequences. 
Statistical analysis  
Fold changes for each cytokine/chemokine mRNA response were normalized by 
log-2 transformation prior to statistical analysis (data were not normally distributed). 
Transformed data were then analyzed using the Linear Mixed Model (LMM) (Repeated 
Measures - Type III sum of squares and diagonal repeated covariance) procedure for 
comparisons of changes in gene expression among treatments and across time. In this 
analysis, “horse” is considered the random factor and “day”, “treatment” and “day x 
treatment” interactions considered as the fixed factors. The transformed fold changes 
corresponded to the response variable. This analysis allows for unsystematic variability 
of the data and provides greater power to detect effects. In this method, the covariance of 
errors is estimated and then used to constrain the error covariance matrix to derive the 
mean squares estimates of the effects. This method provides a way for modeling error 
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structures among the repeated dependent variables and avoids Type I errors, it is also 
used for unbalanced sets of data. In addition, independent t-tests were conducted on each 
separate date to compare mean values between EAIV17 versus mock infected control, 
EAIV17 versus EIAV17ΔS2 and EIAV17ΔS2 versus mock-infected control and to determine 
differences in gene expression that occurred across treatments on each day. The 
statistical package SPSS 15.0 (SPSS Inc. 2007) was used to perform these analyses. All 
data were expressed as mean value (log2) ± S.E.M. Results were considered 
significantly different when p < 0.05. 
Results 
Assay validation  
PCR efficiency for each primer/probe set was determined from the slope of the 
standard curve generated from the serial dilutions of cDNA. A standard curve slope of -
3.32 indicates a PCR reaction with 100% efficiency. Generally, efficiency between 90-
110% is considered acceptable. For all the primer/probe sets, PCR efficiencies ranged 
between 93 and 105%. Moreover, the R2 and standard deviation for each primer/probe 
set was >0.99 and ≤0.13 respectively, indicating overall assay precision (Table 2.2). To 
account for differences in PCR efficiencies, the Pfaffl method was used to determine the 
relative expression of the target genes (Pfaffl, 2001). A single band of expected size was 
obtained using each primer/probe set (Fig. 2.1). In addition sequence analysis confirmed 
the amplification of the target sequences (data not shown).  
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Table 2.2. Validation TaqMan primer/probe sets and SYBR Green primers* 
Target Gene PCR efficiency  
       Mean slope                             %                               R2 
MCP-1 -3.34±0.05 99 0.99 
MCP-2 -3.34±0.11 99 1 
MIP-1α -3.31±0.03 100 1 
MIP-1β -3.19±0.13 105 1 
IP-10 -3.27±0.06 102 0.99 
IL-10* -3.26±0.00 102 0.99 
IL-34* -3.48±0.07 93 0.99 
18S* -3.35±0.00 99 0.99 
Beta-actin* -3.28±0.03 101 0.99 
Note: TaqMan primer/probe sets for IL-1α, IL-1β, IL-6, IL-8, TNF-α and18S have been previously 
described and validated (Allen et al., 2007). 
 
 
 
Figure 2.1. Validation real time PCR products. Products were analyzed by agarose gel electrophoresis 
to verify amplification of single products of the expected size. The 100 bp ladder is in lane 1. 
 
Viral infectivity and mRNA expression 
Viral infectivity of the purified stocks was verified by reverse transcriptase assay. 
Viral stocks remained infectious after purification and concentration and showed similar 
replication kinetics at an MOI of 3 (Fig. 2.2A). These data are in agreement with 
previously published reports that S2 is not required for efficient EIAV replication in 
cultured cells. During the course of EIAV infection in eMDMs, we also monitored the 
levels of viral transcription by real time PCR. As shown in Figure 2.2B, delta cycle 
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threshold (ΔCt) values were gradually decreased over time, indicating an increase in 
viral gene transcription. No differences in the levels of viral transcripts were observed 
between wild-type and S2-deleted viruses during the cytokine/chemokine time course 
experiment. Moreover, no evidence of contamination with wild-type sequences was 
observed during infection with the mutant virus (Fig. 2.3).  
 
 
Figure 2.2. (A) Growth kinetics of viral stocks. eMDMs were infected at a multiplicity of infection 
(MOI) of 3 with EIAV17 (), EIAV17ΔS2 (▲), or mock-infected (■). Culture media were harvested at the 
indicated time points after infection and viral replication was monitored by measurement of reverse 
transcriptase (RT) activity. (B) Real time PCR detection of viral mRNA transcripts during the experiment 
depicted in Figure 2.  Three sets of eMDM cells were infected with EIAV17 () or EIAV17ΔS2 (▲) at an 
MOI of 3. RNA from infected cells were collected at the indicated time points then subjected to reverse 
transcription and amplified in the presence of EIAV specific primers. Viral mRNA was normalized against 
18S mRNA levels. The error bars indicate the standard deviation from three horses (n =3).  The data 
shown in Panels A and B are from separate experiments. 
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Figure 2.3. Detection of EIAV viral transcripts. (A) PCR with specific primers spanning the splice site 
used to generate the single spliced, tricistronic mRNA that encodes Tat, S2 and Env. (B) PCR with 
specific primers bearing the S2 mutation, used to screen for contamination of wild-type sequences. The 
100 bp ladder is in lane 1. PCR was performed 1-4 days post-infection. 
 
Cytokine/chemokine expression in EIAV infected eMDMs 
To study the expression profiles of a set of equine cytokines and chemokines in 
response to EIAV infection and examine the role of S2 in regulating this response, we 
monitored the mRNA expression of 12 cytokines known to play a role in the 
immunopathogenesis of retroviral infections. As shown in Figure 2.4, there was a clear 
effect in the cytokine and chemokine mRNA levels in response to EIAV infection. 
Analysis of the expression data (Table 2.3) shows that following EIAV17 infection, there 
was a statistically significant increase (p < 0.05) in the expression of IL-1β, IL-8, IL-34 
and MCP-2 from days 1 to 4 post-infection compared with the mock-infected control. 
Levels of TNF-α, MCP-1, MIP-1β and IP-10 mRNA were significantly upregulated 
from day 2 to 4 days post-infection. IL-6 and MIP-1α were only induced significantly 
above the baseline levels at days 3 and 4 post-infection. Also, during the first 3 days 
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post-infection, the levels of IL-1α were significantly increased relative to the control. 
There was not a statistically significant difference in the expression of IL-10 at any of 
the time points examined, although there was a subtle decrease in expression compared 
with the control (Fig. 2.4). 
Comparative analysis in the cytokine response between the wild-type virus and 
the S2-deleted virus showed that there is a pattern of enhancement in the 
cytokine/chemokine response in eMDMs infected with the wild-type virus (Fig. 2.4). 
There was a statistically significant difference in gene expression of IL-8 and MCP-2 
from day 1 to 3 post-infection (p < 0.05) between the EIAV17 and S2 mutant viruses. 
Moreover, levels of IL-1α and IL-1β mRNA were significantly increased in cells 
infected with EIAV17 compared with S2-deleted virus at day 2, MIP-1β at day 3 and IP-
10 at days 2 and 3 post infection (Table 2.3).  
In the course of studying cytokine and chemokine profiles during EIAV 
infection, IL-34 was identified in an equine oligo microarray study to be upregulated 
upon EIAV infection (unpublished data). Therefore, we examined the gene expression 
profile of this newly discovered cytokine. When eMDMs were infected with the wild 
type virus, IL-34 was upregulated more than 2-fold during the course of the infection 
with significant differences in gene expression compared with mock-infected or 
EIAV17ΔS2 infected cells (p < 0.01) at all time points tested. Moreover, in contrast to 
other tested genes, IL-34 mRNA levels in cells infected with EIAV17ΔS2 were similar to 
those observed in mock-infected control at all time points. 
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Values represent the mean log2 fold change of infected relative to mock-infected control. Independent t-
tests were conducted to compare mean values for EIAV17 vs mock infected control (Mean17 column), 
EIAV17ΔS2 vs mock infected control (Mean17ΔS2 column) and EIAV17 vs EIAV17ΔS2.  Bolded values indicate 
statistically significant (p < 0.05) changes in gene expression compared to the control (control values are 
constant and are not presented in the table; p-values for these comparisons are not presented in the table). 
Different letters indicate significant differences between EIAV17 and EIAV17ΔS2. Results were considered 
significantly different when p < 0.05. p-values shown in the table describe the EIAV17 vs EIAV17ΔS2 
comparison. 
 
 
 
 
 
 
 
 
Table 2.3. Comparison of cytokine/chemokine gene expression in EIAV17 and EIAV17∆S2 
infected eMDM 
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 Figure 2.4. Time course of cytokine/chemokine mRNA expression in infected eMDM. EIAV17 (), 
EIAV17ΔS2 (▲), or mock-infected (■). Data was analyzed using the Pfaffl method (Pfaffl, M.W. 2001). All 
values were normalized to the endogenous control 18S or b-actin, and represent the log2 mean fold change in 
expression (relative to mock-infected control). Error bars represent ± SEM from six different horses (n =6).  
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Since out-bred horses were used in the study (n=6), there was considerable donor 
to donor variation in the cytokine response to EIAV infection. The greatest donor to 
donor variability in the response between EIAV17 and EIAV17ΔS2 was observed at day 4 
post-infection. Thus, although there was not an overall statistically significant difference 
in the induction of IL-8, MCP-2, MIP-1β and IP-10 between the two viruses at day 4 
post-infection, there was a marked difference in the response among horses. For 
example, IP-10 gene expression varied from 1 to 18 fold in cells infected with EIAV17 
compared with EIAV17ΔS2 (data not shown).  
Examining the kinetics of gene expression shows that IL-6, IL-8, TNF-α, MCP-
2, MIP-1α, MIP-1β and IP-10 upregulation was minimal early during infection but 
gradually increased until the last time point examined. Levels of IL-1β were gradually 
decreased over time but significantly higher than the control at day 4 post-infection. IL-
34 transcripts levels were significantly upregulated early in infection and remained 
steady during the course of infection. For IL-10 there was a subtle, although not 
statistically significant decrease in expression relative to the control. No significant 
changes in MCP-1 expression were detected over time (Fig. 2.4). 
To clearly delineate the effect of S2 in cytokine dysregulation, we also analyzed 
the overall cytokine and chemokine response during EIAV infection. Similarly, the 
results showed that there is a significant effect of EIAV infection in the 
cytokine/chemokine response in eMDM (Fig. 2.5).  
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Figure 2.5. Overall cytokine and chemokine expression of eMDM infected with EIAV17 () or 
EIAV17ΔS2 (■). Bars represent the overall mean log2 fold change in expression relative to mock-infected 
control; mean was obtained by using means per date divided by the number of observed dates. Error bars 
represent ± SEM from six different horses (n =6). Linear mixed model (LMM) was used to determine 
whether or not significant differences occurred. **, indicates p < 0.01. 
 
eMDM infection with EIAV17  significantly upregulated the mRNA expression of 
IL-1α and β, IL-6, IL-8, IL-34, TNF-α, MIP-1β, MCP-1, MCP-2 and IP-10 (p = 0.00) 
and MIP-1α (p = 0.02) relative to the mock-infected cells. Moreover, the presence of S2 
strongly enhanced mRNA expression of IL-1α, MIP-1β, IP-10  (p = 0.01), IL-1β, IL-8, 
IL-34 and MCP-2, (p = 0.00) compared with the EIAV17ΔS2 virus. However, the levels of 
IL-6, IL-10, TNF-α, MCP-1 and MIP-1α showed no statistically significant changes 
overall during infection (p > 0.05) compared with S2 deleted virus.  
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Discussion 
A main feature of lentiviral infection is dysregulated expression of cytokines and 
chemokines. During the course of HIV, SIV, and FIV infections, cytokines are known to 
modulate viral replication, persistence and disease progression in the host (Dean and 
Pedersen, 1998; Kedzierska et al., 2003; Orandle et al., 2001). The modulation of the 
cytokine/chemokine response during the course of EIAV infection has not been as fully 
elucidated. It has been shown that early during infection (0.5-1 h post-infection) there is 
a pro- and anti-inflammatory response to EIAV infection in vitro (Lim et al., 2005), 
however the dynamics of cytokine response during the course of EIAV replication in 
horses is unknown. Changes in cytokine and chemokine levels during the course of 
EIAV infection could have a major impact on the immune system, influencing 
pathogenesis by enhancing or suppressing EIAV replication as well as favoring the 
formation of infected cell reservoirs. We undertook this study to further examine the 
effect of EIAV in modulating the cytokine and chemokine response in macrophages 
during the course of infection and to determine if the EIAV S2 protein has a role in 
modulating this response. Our results confirm that EIAV induces a strong pro-
inflammatory response in eMDM and that S2 enhances this response.  In light of the 
clearly demonstrated role of S2 in disease expression (Fagerness et al., 2006; Li et al., 
2000) it is possible that a robust pro-inflammatory response is advantageous for the virus 
in the infected animal. In fact, pro-inflammatory cytokines/chemokines such as IL-1, IL-
6, IL-8, TNF-α and IP-10, among others are known to stimulate HIV replication (Ott et 
al., 1998; (Lane et al., 2003).  
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In the current study we show significantly increased levels of TNF-α, IL-1α, IL-
1β, IL-6, IL-8, IP-10, IL-34, MCP-1, MCP-2, MIP-1α and MIP-1β in EIAV-infected 
eMDM relative to uninfected controls. These results correspond to studies of EIAV 
infected foals where increased levels of TNF-α and IFN-α are found in association with 
high levels of viremia and are increased in the serum and bone marrow just before the 
onset of thrombocytopenia (Tornquist et al., 1997). IL-1 β and IL-8 are also associated 
with marked thrombocytopenia (Bozza et al., 2008); whether or not dysregulation of 
these cytokines contributes to the  development of thrombocytopenia during EIAV 
infection needs to be determined.  
IL-10 was the only anti-inflammatory cytokine monitored in the study. IL-10 
strongly inhibits the production of a wide variety of inflammatory mediators in 
macrophages, T cells and B cells (de Waal Malefyt et al., 1991; Moore et al., 2001) and 
IL-10 decreases HIV replication in macrophages (Akridge et al., 1994). In our study IL-
10 expression was not increased by EIAV infection; in fact there was a subtle decrease 
relative to the control. This result corroborates our findings that EIAV replication favors 
the induction of a pro-inflammatory response and that at least during the first days post-
infection, this response is unlikely to have an antiviral effect.  
EIAV infection also strongly stimulated gene expression levels of the 
chemokines IP-10, IL-8, MCP-1, MCP-2, MIP-1α and MIP-1β during the course of 
infection. The up-regulation of chemokine levels during EIAV infection could explain 
the accumulation of lymphocytes and macrophages in the spleen, lymph nodes, lungs 
and other tissues in EIAV infected horses (McGuire et al., 1990) and could play an 
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important role in disease progression. Increased IP-10 and IL-8 expression during HIV 
infection stimulates viral replication in macrophages and T cells (Lane et al., 2003; Lane 
et al., 2001). Moreover, dysregulation of theses chemokines have been implicated in the 
intensity and progression of HIV disease (Kinter et al., 1998; Reinhart, 2003; 
Schmidtmayerova et al., 1996).  
Although MIP-1α and MIP-1β are closely related pro-inflammatory chemokines, 
they have distinctive biological properties. Both strongly induce chemotaxis of 
monocytes and macrophages and are potent pyrogens (Maurer and von Stebut, 2004; 
Menten et al., 2002; Minano et al., 1996). MIP-1α but not MIP-1β suppresses cell 
proliferation of granulocyte-macrophage (CFU-GM), erythroid (BFU-E) and 
multipotential (CFU-GEMM) progenitors from bone marrow cells in vivo and in vitro 
(Maze et al., 1992). Interestingly, MIP-1β acts specifically to block the inhibitory effect 
of MIP-1α, suggesting a synergy between these two chemokines to regulate proliferation 
of myeloid progenitor cells (Broxmeyer et al., 1993; Broxmeyer et al., 1991).  
Analysis of the role of S2 in cytokine/chemokine expression indicates that S2 
plays an overall enhancing role in the upregulation of proinflammatory cytokines and 
chemokines. S2 had a significant effect on expression of IL-1α, IL-1β, MIP-1β, IP-10, 
MCP-2, and IL-8. The difference in expression levels between S2-deleted and the 
parental virus was not significant for IL-6, TNF-α or MIP-1α, although cytokine 
expression was somewhat decreased for the S2-deleted virus.  These results, together 
with in vitro studies of Lim et al. (2005) that describe a role for EIAV SU in the 
induction of proinflammatory cytokines in eMDM, and Payne et al. (Payne et al., 2004) 
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and Fagerness et al. (2006) that reveal roles of SU and S2 respectively in disease 
expression suggest a scenario whereby EIAV SU and S2 act in concert to produce a 
robust proinflammatory cytokine response that promotes vigorous virus replication, 
fever and thrombocytopenia. 
IL-34 is a newly discovered cytokine without significant amino acid sequence 
homology to other cytokines or proteins. IL-34 is expressed in a wide variety of tissues 
including liver, kidney, thymus, brain and spleen. In vitro, IL-34 specifically binds to 
monocytes and stimulates their proliferation and/or survival. In addition, IL-34 promotes 
the differentiation of bone marrow cells into a macrophage progenitor known as colony-
forming unit-macrophage (CFU-M), which in turn give rise to a homogenous population 
of macrophages (Lin et al., 2008). At the amino acid sequence level, equine IL-34 shares 
85%, 75% and 71% pairwise sequence identity with bovine, human and mouse 
respectively.  
Our results clearly showed that EIAV infection of eMDM increased the 
expression of IL-34. Since the S2-deleted virus failed to increase the mRNA levels 
above the baseline, this indicates a specific role for S2 in the upregulation of mRNA 
levels of this cytokine during infection. Interestingly, among all the cytokines and 
chemokines tested, IL-34 was the only cytokine to be solely affected by the presence of 
S2.  These data underline the need for additional studies to determine the role, if any, of 
S2 in monocyte proliferation and survival through upregulation of IL-34 expression 
particularly as monocyte differentiation into macrophage is a prerequisite for a 
productive EIAV infection. Interestingly, IL-34 promotes the formation of 
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monocyte/macrophage lineage cells in the bone marrow, so it will be worth testing 
whether or not S2 has an essential role in regulating the proliferation of macrophage 
progenitors. A modulation of monocyte/macrophage lineage proliferation could in turn 
increase the pool of target cells available for infection having a profound effect in the 
pathogenesis of EIAV infection. In contrast with HIV, SIV and FIV infection where 
there is a suppression of bone marrow granulocyte/macrophage progenitor cells 
(Linenberger et al., 1991; Prost et al., 2008; Steinberg et al., 1991), EIAV is unique in 
that during the course of infection there is not an apparent inhibitory effect in the 
formation of granulocyte/macrophage progenitor cells (Swardson et al., 1992).  
In summary, our study indicates that S2 is not solely responsible for the 
modulation of the cytokine responses during EIAV infection but supports the possibility 
of S2 as a contributing factor in cytokine dysregulation, exacerbating disease 
progression. Cytokine enhancement by S2 may promote a suitable cellular environment 
that is likely to promote viral replication and dissemination, having a major impact in 
viral pathogenesis and disease progression. 
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CHAPTER III 
PROBING THE FUNCTION OF THE EIAV S2 PROTEIN USING AN EQUINE 
WHOLE GENOME OLIGONUCLEOTIDE ARRAY 
 
Overview 
EIAV is a macrophage-tropic lentivirus that causes persistent infection in horses. 
Studies have shown that the EIAV accessory protein S2 makes an important contribution 
to virulence, but the mechanism by which S2 modulates pathogenesis remains unclear. 
Ponies infected with the highly virulent molecular clone EIAV17 experience severe 
febrile episodes accompanied by a significant decrease in platelet numbers and a high 
viral load, as seen in natural infections. In contrast, ponies infected with a deleted-S2 
virus, EIAV17∆S2, display reduced virus replication and fail to develop disease. In this 
study we used an equine whole genome oligonucleotide array to identify genes and 
predict cellular processes that are affected during infection of primary macrophages with 
virulent EIAV and to compare those with macrophages infected with an S2-deleted 
virus. Microarray data revealed 106 genes that were differentially expressed (compared 
with mock-infected) following infection with virulent EIAV. Comparison of virulent 
EIAV to the S2-deleted virus revealed 273 differentially expressed genes. Differentially 
expressed genes included those involved in immune response, transcription, translation, 
cell cycle and cell survival. Microarray results were validated for selected genes by 
quantitative real time PCR. 
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Introduction 
EIAV is a lentivirus of the family Retroviridae that naturally infects horses and 
induces a disease characterized by three distinctive stages: acute, chronic and innaparent 
(Cheevers and McGuire, 1985). The acute stage occurs within a week to a month from 
the initial exposure, which is relatively fast compared with other lentiviral infections. 
Fever, thrombocytopenia and high levels of viremia are some of the characteristics 
symptoms of this stage (Payne, 2006). The chronic phase is associated with several 
recurrent episodes of the acute symptoms that can last 8-12 months post-infection, 
followed by an inapparent carrier stage (Craigo et al., 2006). One of the unique aspects 
of the pathogenesis of EIAV infection is that a high percentage of infected horses (90%) 
recover from the chronic infection to become asymptomatic carriers of the virus (Craigo 
et al., 2009). 
The S2 gene, unique to EIAV, encodes a small 65 amino acid, 7 kDa protein that 
plays a critical role in disease expression in the infected horse. The S2 open reading 
frame (ORF) begins just downstream the second exon of tat and overlaps the 5’ end of 
the env gene. S2 is synthesized at a late phase of the viral life cycle by a leaky ribosome 
scanning mechanism from either bicistronic or tricistronic mRNA encoding Tat, S2 and 
Env (Carroll and Derse, 1993; Schiltz et al., 1992). Examination of S2 viral sequences 
from natural or experimentally infected horses reveals a high level of conservation, 
indicating it plays an important role in the natural infection (Craigo et al., 2009; Leroux 
et al., 2004; Li et al., 2000). Moreover, amino acid sequence alignments of S2 reveal 
several conserved, well-characterized protein motifs: an N-terminal myristoylation 
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motif, the proline rich (PXXP) SH3 domain binding motif, the nucleoporin motif 
(GLFG) and the nuclear localization signal (RRKQETKK) motif (Leroux et al., 2004; Li 
et al., 2000).  
The role of S2 during viral infection was first evaluated in several cultured 
equine cell systems infected with wild-type and S2-deleted molecular clones. It was 
found that S2 is not essential for viral replication in cultured cells, although its presence 
may slightly increase viral replication in vitro (Fagerness et al., 2006; Li et al., 1998). 
Later on, the pivotal role of S2 in EIAV infection came from studies using the Shetland 
pony model. In one study, ponies infected with a virus derived from EIAV17, a highly 
virulent molecular clone, displayed the typical signs of equine infection anemia (EIA), 
including key features such as: febrile episodes, thrombocytopenia, and high levels of 
viremia. In contrast, ponies infected with an S2-deleted virus (EIAV17∆S2) had a 
decreased viral load and failed to develop any clinical signs of the disease (Fagerness et 
al., 2006). These data indicate that S2 is an important determinant in EIAV pathogenesis 
in vivo. 
The underlying mechanism(s) by which S2 enhances viral replication and 
influences disease expression, while unknown are under investigation. We recently 
reported that S2 enhances the expression of a variety of pro-inflammatory cytokine and 
chemokine genes suggesting a role for S2 in optimizing the host cell environment for 
viral replication and dissemination (Covaleda et al., 2009). In this study, to further 
elucidate the role of S2 in pathogenesis we employed an equine whole genome 
oligonucleotide array (Bright et al., 2009) to provide a global view in gene expression 
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patterns in macrophages infected with EIAV wild-type and S2-deleted mutant virus. 
This study is an important step toward identifying cellular processes affected during 
EIAV infection and also may give us clues as to the role of S2 in pathogenesis. 
Materials and Methods 
Culture of equine monocyte-derived macrophage cell culture (eMDM) 
Whole blood was collected from six EIA-negative healthy adult horses and 
centrifuged at 2100 rpm for 30 min to separate the buffy coat, which was then diluted 
1:3 with Hank’s balance salt solution (HBBS) containing 2 mM EDTA. Fifteen ml of 
endotoxin-free Histopaque-1077 (Sigma-Aldrich) was slowly layered underneath 20 ml 
of diluted buffy coat and centrifuged at 2100 rpm for 30 min at room temperature. 
Peripheral blood mononuclear cells (PBMCs) were harvested from the interface and 
washed by centrifugation at 1000 rpm for 10 min at 4 °C in cold entodoxin-free 
Alsever’s solution (0.1M D-glucose, 0.027 M sodium citrate, 0.002 M citric acid, 0.07 
M sodium chloride, pH 6.1) containing 1% penicillin-streptomycin, to remove platelets. 
Residual erythrocytes were lysed by incubation with 5 ml ACK lysis buffer (Invitrogen) 
for 3 min at 37 °C.  After washing three times with 50 ml Alsever’s solution, PBMCs 
were resuspended in RPMI 1640 medium supplemented with 10% heat-inactivated horse 
serum, penicillin (100 IU/ml), streptomycin (100µg/ml), and L-glutamine (2 mM). For 
monocyte isolation by plastic adherence, 12 x 106 PBMC per well were seeded into 12-
well plates (BD Falcon) and allowed to adhere overnight in a 37 °C humidified 5% CO2 
incubator. Nonadherent cells were removed by gently washing the plates, twice, with 
prewarmed RPMI complete media and the remaining adherent monocyte-enriched cells 
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were allowed to differentiate for further 48 h before infection. All reagents were 
screened and found negative for endotoxin and mycoplasma contamination using the 
Limulus Amebocyte lysate kit (Associates of Cape Cod) and MycoFind Kit (Clongen 
laboratories) respectively. 
Virus preparations 
Virus stocks were generated as previously described (Lim et al., 2005). Briefly, 
D17 cells were transfected with 10 µg of the molecular clones EIAV17 or EIAV17∆S2 
plasmids by using the calcium phosphate method and virus particles harvested 72 h post-
transfection were used to infect eMDMs. Culture supernatants collected from 7 to 15 
dpi, were removed from infected eMDMs and cleared of cell debris by low-spin 
centrifugation. Virus stocks were assayed for reverse transcriptase (RT) activity as a 
measure of virus replication. Virus stocks were purified and concentrated via 
ultrafiltration using a Vivaflow 200 tangential flow system with a 100 kDa MWCO filter 
(Sartorius). After ultrafiltration, maintenance of virus infectivity was confirmed by 
growth in eMDMs and RT activity. No detectable levels of endotoxin were present in the 
purified virus stocks. Viral infectivity titers were determined by the Reed-Muench 
formula after infecting eMDMs with 10-fold serial dilutions of the virus in sextuplicates 
and maintaining the culture for two weeks. 
Infection of eMDM 
Three days post-plating, eMDM were mock infected (with cell culture media 
used to grow the cells), infected with EIAV17 or EIAV17∆S2 at a multiplicity of infection 
(MOI) of 3 to achieve a near synchronous infection. Supernatants and cell extracts were 
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collected 72 h post-infection. Virus replication was monitored by measurement of RT 
activity, cytopathic effect (CPE) and viral mRNA transcription. 
RNA isolation, amplification and labeling 
At 72 h post-infection cells were harvested in RLT buffer (QIAGEN) and cell 
pellets were stored at -80 °C until ready for RNA isolation. Total RNA was isolated 
using the RNeasy kit from QIAGEN, including DNaseI digestion according to 
manufacturer’s instructions. RNA was further assessed for quality and concentration 
using the Nano 6000 assay on the Agilent 2100 Bioanalyzer. Since microarray 
experiments require RNA in microgram quantities for hybridization, 500 ng of total 
RNA were used for one round of linear amplification using the senseAMP Plus kit 
(Genisphere). Amplified RNA (2 µg) was then used as a template to generate Cy3 or 
Cy5 tagged cDNA probes (Genisphere). Cy5 tagged cDNA probes were generated from 
wild-type and mutant samples and Cy3 tagged cDNA probes were generated from mock-
infected control samples. The tagged cDNA probes were reversed in terms of dye 
labeling for samples obtained from the other three horses to offset potential dye bias. 
Shown in figure 3.1 is a flow diagram of the experimental design used. 
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Figure 3.1. Flow diagram of the array experimental design.  
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Microarray hybridization and data collection  
Prior to hybridization, printed oligo-microarray slides were: (1) rehydrated over a 
50 °C water bath for 10 seconds (label-side down), (2) snap-dried at 65 °C in a heating 
block for 5 seconds (label-side up) and (3) allowed to cool for 1 minute. Steps 1-3 were 
repeated 3 times. The slides were then UV cross-linked at 750 mJoules. Twenty-eight µl 
of each Cy3 and Cy5 cDNA probe (mock-infected and wild-type or mock-infected and 
mutant) were combined with 290 µl 2X hybridization buffer plus 30 µl of TE, 2 µl LNA 
dT Blocker and 202 µl of nuclease-free water (Array 350 – Genisphere). The 
hybridization mixture was then incubated at 80 °C for 10 min, cooled to room 
temperature and then applied to the gasket slide in a microarray chamber (Agilent) with 
the rehydrated oligo-microarray slide laid on top (label-side down). The microarray-
gasket slide sandwich was then incubated for 16 h at 55 °C in a hybridization rotation 
oven. Following hybridization, oligo-microarrays were washed for 15 min each in 
prewarmed 2X SSC plus 0.2% SDS solution (Ambion) at 42 °C, 2X SSC at room 
temperature and 0.2X SSC at room temperature. Finally, slides were spin-dried by 
centrifugation in 50 ml conical tubes. A second hybridization mixture contained 2.5 µl 
of Cy3 and Cy5 fluorescent 3DNA reagents, 25 µl of 2X hybridization buffer with SDS, 
0.25 µl of anti-fade reagent and 20 µl of nuclease-free water. The hybridization mixture 
was then applied to the pre-hybridized microarray slide and covered with a glass cover 
slip. Slides were incubated in the dark at 55 °C for 4 h. Post-hybridization washes and 
spin-dry were repeated as before but in the dark. Oligo-microarrays were stored in the 
dark until scanned. Hybridized oligo-microarrays were scanned at 5 micron resolution 
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using a GenePix 4100A scanner and GENEPIX 6.0 analyzer software was used to 
process microarray images, locate spots and to obtain raw total spot intensities for both 
dyes in each spot (Axon Instruments / Molecular Devices). 
Microarray analysis 
Raw data from mean spot intensity and median background intensity was Lowess 
normalized to reduce the intra and inter-array variability that are commonly observed in 
microarray experiments (Park et al., 2003). In addition raw data was filtered to exclude 
spots with a signal to noise ratio ≤2 or a GenePix flag. A mixed model analysis was 
applied to the normalized log2 ratios to identify genes differentially expressed between 
the treatment groups. The mixed model included the effects of treatment, dye, slide and 
replicate in the analysis. List of genes were generated based on two criteria: a fold 
change ≥1.8 or ≤ -1.8 for genes upregulated or downregulated respectively and a p-value 
cutoff of ≤ 0.05. The statistical package SAS was used to perform these analyses.  
Wild-type and delta-S2 infected samples (Cy5) were directly compared to the 
mock-infected control (Cy3). Differences in gene expression between wild-type and 
mutant were compared indirectly through those of the control samples.  
Microarray validation 
TaqMan and SYBR Green based assays were used to analyze and validate gene 
expression levels of selected genes (Table 3.1). TaqMan real time PCR reactions were 
performed in a 10 µl total volume containing 0.5 µl of cDNA, 5 µl of EXPRESS qPCR 
SuperMix with premixed ROX (Invitrogen), 0.5 µl of fluorescent primer/probe mix, and 
4 µl of DEPC-treated water. SYBR Green real time PCR reactions contained 5 µl of 
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SYBR Greener qPCR with premixed ROX (Invitrogen), 200 nM of the primer mix, and 
DEPC-treated water. Amplification was carried out using the following parameters: 50 
°C for 2 min, 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 s and by 60 °C for 
30 s. A dissociation stage was included for SYBR Green real time PCR to confirm the 
amplification of a single product. All RT reactions, including no-template controls, were 
run in triplicate on an ABI 7900HT real-time PCR system. Data were collected and 
analyzed with the SDS 2.3 software. The Pfaffl method (Pfaffl, 2001) was used to 
calculate relative fold changes in gene expression between mock-infected and infected 
samples. Data were first normalized to the endogenous control 18S rRNA or beta-actin 
and the mock-infected samples were used as calibrator. TaqMan primer/probe sets for 
IL-8 and 18S have been previously described and validated (Allen et al., 2007) and were 
obtained from Applied Biosystems. TaqMan probes and primers for SYBR Green real 
time PCR were designed to span at least one exon-exon junction to prevent amplification 
of genomic sequences. TaqMan probes were 5’ labeled with 6-carboxyfluorescein 
(FAM) and 3’ with a nonfluorescent quencher (NFQ). RT-PCR products were separated 
by 2% agarose gel electrophoresis to confirm product size and specificity of each 
primer/probe set. Fragments were also analyzed by sequencing to validate the identity of 
the PCR products. PCR efficiency from each primer/probe set was determined by 
performing a 6-log dilution range from 3 different cDNA samples. Each dilution was run 
in triplicate. 
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Table 3.1. Sequence of primer and probes used in real time quantitative PCR 
Gene  Gene ID # Primer/probe Sequence 5’→3’ Product length (bp) 
IL-8 * 100037400 Forward 
Reverse 
Probe 
 
GCCACACTGCGAAAACTCA 
GCACAATAATCTGCACCCACTTTG 
FAM-ACGAGCTTTACAATGATTTC-NFQ 
95 
MCP-2 * 100033950 Forward 
Reverse 
Probe 
 
TCACCAGCAGCCAGTGTTC 
GCACAGATCTCCTTGTCCACTTT 
FAM-AAGCTGTGATCTTCAAGACC-NFQ 
67 
18S* AJ311673 Forward 
Reverse 
Probe 
 
AAACGGCTACCACATCCAA 
TCGGGAGTGGGTAATTTGC 
FAM-AAGGCAGCAGGCGC-NFQ 
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IL-34 
 
100054703 
 
Forward 
Reverse 
 
TGCCCTTGCTGTAAACATAGC 
CCACACACTGTGATGATGAGG 
 
100 
RANTES  100033925 Forward 
Reverse 
 
AGTCGTCTTTGTCACCCGAAAG 
GCACCCATTTCTTCTCTGCATT 
 
62 
ISG15 100066364 Forward 
Reverse 
 
TGCAGGCCGACCAGTTCT 
ACTGTGCACCCGGCTGTAA 
94 
MMP-9 
 
CD63 
100056599 
 
100051450 
Forward 
Reverse 
 
Forward 
Reverse 
 
GCGCTCATGTACCCCATGTA  
GCGAGGACCATAGAGATACTGGAT 
 
CAAGGGCTGTGTGGAGAAGATT 
AATTCCCAGGACCTCCACAAA 
90 
 
 
100 
 
 
DNM3 
 
HMG-1 
100060156 
 
100050136 
Forward 
Reverse 
 
Forward 
Reverse 
TGAAAGTGCGAGATGTGGAAAA  
AGTCTTTGTAAACATTCCTTTGTTCAGT 
 
GCGGACAAGGCCCGTTAT 
AGGTGCATTGGGATCCTTGA 
90 
 
90 
 
CHMP1B 
 
100071734 
 
Forward 
Reverse 
 
TGAAGCTGGCCTTGATCTCA 
ACTTGTGCCAACAGAACCTGTCT 
 
64 
 
Beta-actin 
 
100033878 
 
Forward 
Reverse 
 
TCACGGAGCGTGGCTACAG 
CCTTGATGTCACGCACGATTT 
 
63 
    *TaqMan primer/probes sets 
 
Fold changes for each target gene were log-2 transformed prior to statistical 
analysis and statistically significant difference was determined using Student’s t test. All 
data were expressed as mean value (log2) ± S.E.M. Results were considered 
significantly different when p < 0.05. 
 
 
 56 
Results  
EIAV replication and transcription in eMDM cultures 
 To obtain a global view of gene expression patterns induced by EIAV infection 
and the contribution of S2, this study was performed with the highly virulent molecular 
clone EIAV17 and its S2-deleted counterpart (EIAV17∆S2). Gene expression profiles from 
infected samples were analyzed relative to the mock-infected control, to accurately 
evaluate the changes in cellular gene expression. 
Cultured equine macrophages were infected at an MOI of 3 to achieve a near 
synchronous infection and ensure that each cell was infected. This allowed us to clearly 
analyze the cellular response that occurs upon EIAV infection and minimize bystander 
cell responses. To evaluate viral infectivity of the purified stocks, supernatants from 
infected cells and the mock-infected control were collected at different time points and 
assayed for RT activity as a measure of viral replication. As shown in Fig. 3.2A, the 
viral stocks showed similar replication kinetics. Moreover, we also monitored the levels 
of viral transcription by real time PCR with EIAV primers spanning the splice site used 
to generate the single spliced, tricistronic mRNA that encodes Tat, S2 and Env. As 
shown in Fig. 3.2B, no significant differences in the levels of the specific viral transcript 
were observed between wild-type and S2-deleted virus. In this experiment, a decrease in 
delta cycle threshold (∆Ct) values indicates an increase in viral gene transcription. 
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Figure 3.2. Viral infectivity and mRNA expression. (A) Growth kinetics of viral stocks. (B) Real time 
PCR detection of viral mRNA transcripts. The error bars indicate the standard deviation from three horses 
(n=3). The data shown in Panels A and B are from separate experiments. 
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Gene expression profiles in eMDMs after infection with EIAV17 and EIAV17∆S2 
 In a previous study from our lab (Covaleda et al., 2009), we showed that the 
majority of changes in cytokine and chemokine expression in macrophages infected with 
EIAV occurred three days post-infection. For that reason, as a first step to delineate 
changes in cellular gene expression induced by EIAV we chose to initially carry out this 
study with samples collected at 72 h post-infection.  
Since the amount of total RNA obtained in our experiment was too low to 
perform array analysis, RNA samples were subjected to one round of linear 
amplification (Genisphere). Cy3 and Cy5 dye-labeled cDNA probes (mock-infected and 
infected samples, respectively) were hybridized to equine oligonucleotide arrays and 
ratios of signal intensities were calculated at each spot. Samples obtained from three out 
of the six horses used in the study were labeled reversed in terms of dye labeling to 
offset potential dye bias due to sequence-specific dye incorporation. The equine whole 
genome oligonucleotide array kindly provided by Dr Bhanu Chowdhary (Texas A&M 
University) has 21,351 probes representing a genomic coverage of approximately 97.5% 
(Bright et al., 2009). After array normalization, data from 78% of the array spots were 
further used for mixed model analysis to identify genes differentially expressed between 
the treatment groups. 
To determine gene expression profiles and establish gene expression differences 
between treatments, differentially expressed genes were selected based on two criteria, a 
significance level of p<0.05 and a fold change greater than 1.8 up or down regulated. 
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 On the basis of the mixed model analysis, approximately 109 genes were 
differentially expressed upon EIAV infection with the highly virulent virus (EIAV17), 
290 genes were differentially expressed between EIAV17 and the S2-deleted virus 
(EIAV17∆S2) and 30 genes were differentially regulated by the S2-deleted virus relative 
to the mock infected control (p<0.05). Of these significantly regulated genes, a high 
percentage had not been annotated yet. Thirty-five of these unannotated genes are from 
the analysis of EIAV17 versus mock-infected control, 89 from the EIAV17 versus 
EIAV17∆S2 and 6 from the EIAV17∆S2 versus mock-infected control. 
Differentially expressed genes with increased or decreased expression were 
classified by the Swiss-Prot keyword “biological process”. Partial lists of the top 
differentially expressed genes are shown in Tables 3.2 to 3.5. Genes up-regulated during 
EIAV infection include genes that we previously have reported as induced in EIAV 
infected macrophages, such as interleukin-8 (IL-8), monocyte chemotactic protein-2 
(MCP-2) and interleukin-1 alpha (IL-1α), providing support of the validity of the array 
results. Overall, more genes involved in immune response, transcription regulation, 
mRNA splicing, cell cycle, cell survival and the ubiquitin pathway were stimulated 
(Table 3.2). Whereas a lower percentage of genes involved in transcription, immune 
response, cell cycle and cell survival were down-regulated (Table 3.3). Strikingly, genes 
involved in translation were only down-regulated upon EIAV infection; these included 
several ribosomal proteins (RPL17, RPL27A, RPL34, RPL31, RPS25, S6, 16S) and 
eukaryotic translation initiation factor 3 (EIF3F). 
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Table 3.2. Selected up-regulated genes in EIAV wild-type infected macrophages 
classified by Swiss-Prot keyword 
Gene ID Gene name Fold change  
Immune response  
LOC100037400 
LOC100033927 
Interleukin-8 (IL-8) 
Monocyte chemoattractant protein-2 (MCP-2) 
2.2 
4.8 
LOC100033925 RANTES 2.0 
LOC100064969 Interleukin-1 alpha (IL-1a) 1.8 
LOC100053534 Immunoglobulin-like transcript 8 (ILT8) 1.9 
LOC100070878 Interferon, gamma-inducible protein 30 (IP-30) 2.0 
 
Transcription regulation and mRNA splicing  
LOC100051665 RuvB-like 2 (RUVBL2) 2.6 
LOC100068414 Cysteine-serine-rich nuclear protein-1 (CSRNP-1) 2.1 
LOC100146801 Jun B proto-oncogene (Jun-b) 2.0 
LOC100056571 CREB regulated transcription coactivator 2 (CRTC2) 1.9 
LOC100034223 Superoxide dismutase-2 (SOD2) 2.1 
LOC100058690 RNA binding motif protein 4 (RBM4) 3.2 
 
Cell cycle and proliferation  
LOC100055960 G1 to S phase transition-1 (GSPT-1) 2.3 
LOC100072415 Serpin peptidase inhibitor, clade F (SERPINF1) 2.1 
LOC100054703 Interleukin-34 (IL-34) 1.9 
LOC100061408 Dedicator of cytokinesis-3 (DOCK3) 1.9 
LOC100053929 Interferon stimulated exonuclease gene-20 (ISG20) 1.9 
LOC100034223 Superoxide dismutase-2 (SOD2) 1.1 
LOC100064022 Cyclin-dependent kinase inhibitor 1A, p21 (CDKN1A) 1.8 
 
Ubl conjugation pathway and antiviral defense  
LOC100065188 Ring finger protein 182 (RNF182) 2.6 
LOC100052084 Murine double minute 2 oncogene (MDM2) 2.5 
LOC100066364 
Interferon stimulated gene 15 (ISG15) - ubiquitin-like 
modifier  2.3 
LOC100071433 Ubiquitin specific peptidase 47 (USP47) 2.0 
LOC100068894 Baculoviral IAP repeat-containing 3 (BIRC3) 1.9 
AY509556 2'-5'-oligoadenylate synthetase 2 (OAS2) 1.9 
LOC100053929 Interferon stimulated exonuclease gene-20 (ISG20) 1.9 
LOC100052688 Fem-1 homolog b, transcript variant 2 (FEM1B) 1.9 
 
Cell death and survival  
LOC100061755 BCL2-antagonist/killer 1 (BAK1) 2.0 
LOC100068894 Baculoviral IAP repeat-containing 3 (BIRC3) 1.9 
LOC100034223 Superoxide dismutase-2 (SOD2) 2.1 
LOC100068414 Cysteine-serine-rich nuclear protein-1 (CSRNP-1) 2.1 
 
Signal transduction  
LOC100051866 Growth factor receptor-bound protein 2 (GRB2) 2.0 
LOC100067361 Signal-regulatory protein beta 1 (SIRPB1) 2.0 
 
Others   
LOC100072671 Vacuolar protein sorting 26 homolog A (VPS26A) 2.6 
LOC100052051 Barrier to autointegration factor 1 (BANF1) 2.1 
LOC100051102 RNA binding motif protein 42 (RBM42) 1.9 
LOC100066372 Zinc finger protein 385B (ZNF385B) 1.8 
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Table 3.3. Selected down-regulated genes in EIAV wild-type infected macrophages 
classified by Swiss-Prot keyword 
Gene ID Gene name Fold change 
Immune response  
LOC100057478 Thrombospondin 1 (TSP1) -4.3 
LOC100065481 Apolipoprotein E (APOE) -2.8 
LOC100056599 Matrix metallopeptidase 9 (MMP9) -2.3 
 
Transcription regulation and mRNA splicing  
LOC100050136 High-mobility group box 1 -4.0 
LOC100051444 TGFB-induced factor homeobox 1 (TGIF1) -2.6 
LOC100066520 Polymerase (RNA) I polypeptide E (POLR1E) -2.5 
LOC100066265 DEK oncogene -2.0 
LOC100052973 Forkhead box N3 (FOXN3) -1.8 
 
Cell death and survival  
LOC100060183 p21 protein-activated kinase 2 (PAK2) -7.0 
LOC100057478 Thrombospondin 1 (TSP1) -4.3 
LOC100050136 High-mobility group box 1 (HMGB1) -4.0 
LOC100072241 Annexin A5 (ANXA5) -3.2 
LOC100053396 Glutathione peroxidase 1 (GPX1) -2.5 
LOC100053958 Cytochrome c (CYCS) -2.0 
LOC100063318 Protein kinase C (PRKCA) -1.9 
 
Cell cycle  
LOC100071734 Chromatin modifying protein 1B (CHMP1B) -1.9 
LOC100052973 Forkhead box N3 (FOXN3) -1.8 
 
Translation  
LOC100056788 Ribosomal protein L34 (RPL34) -2.5 
LOC100071004 Ribosomal protein L27a (RPL27A) -2.3 
CD466522 Ribosomal 16S RNA gene -2.3 
LOC100052368 Ribosomal protein S6 -2.1 
LOC100053716 Ribosomal protein L17 (RPL17) -2.1 
LOC100059235 Ribosomal protein L31 (RPL31) -2.0 
LOC100063216 Ribosomal protein S25 (RPS25) -2.0 
LOC100070877 Eukaryotic translation initiation factor 3, F (EIF3F) -1.9 
 
Others   
LOC100050663 Lymphocyte cytosolic protein 1 (LCP1) -2.1 
LOC100050835 Cystatin B (CSTB) -2.1 
LOC100051450 CD63 antigen (CD63) -1.8 
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Even though we amplified the RNA to obtain enough material to perform the 
microarray experiment, it was not sufficient to carry out a direct experimental design 
method where we could compare, in the same array slide, the EIAV17 versus EIAV17∆S2 
treatments. Instead, we used an alternative approach using indirect comparisons to 
evaluate differences in gene expression profiles between macrophages infected with the 
wild-type and S2-deleted viruses (Speed and Yang, 2002).  
Similar to the results obtained with the EIAV17 versus mock-infected cells, genes 
up-regulated in macrophages infected with EIAV17 compared with the S2-deleted virus 
are involved in the immune response, transcription, cell death, cell cycle and antiviral 
defense. The majority of the differentially expressed genes are different from those 
genes found to be increased in the EIAV17 versus mock-infected analysis (Table 3.4). 
 Genes that were decreased in cells infected with EIAV17 when compared with 
the mutant virus were found to encode proteins involved in the immune response, 
translation, cell death and transcription (Table 3.5). Some of the common genes down-
regulated are matrix metallopeptidase 9 (MMP9), cystatin B (CSTB), forkhead box N3 
(FOXN3), high-mobility group box 1 (HMGB1) and ribosomal proteins, RLP27A, 
RPL31 and RPL36A. 
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Table 3.4. Selected up-regulated genes in EIAV wild-type versus EIAV S2- deleted 
infected macrophages classified by Swiss-Prot keyword 
Gene ID Gene name Fold change 
Immune response  
LOC100064969 Interleukin-1 alpha (IL-1a) 2.0 
DN507662 Human microRNA host gene 2- MIRHG2 (BIC) 2.0 
LOC100053534 Immunoglobulin-like transcript 8 (ILT8) 2.3 
LOC100066223 Signal transducing adaptor family member 1 (STAP1) 2.3 
 
Transcription regulation and mRNA splicing  
LOC100061235 Zinc finger protein 568 (ZNF568) 2.5 
LOC100055527 GA binding protein transcription factor (GABPB2) 2.3 
LOC100058395 Zinc finger protein 207 (ZNF207) 2.0 
LOC100063879 Nuclear receptor subfamily 2 (NR2E3) 2.0 
LOC100071307 Ring finger protein 141 (RFN141) 1.8 
LOC100066388 cAMP responsive element binding protein 1 (CREB1) 1.8 
LOC100050857 Retinoblastoma binding protein 8 (RBBP8) 1.8 
LOC100068168 Smu-1 suppressor of mec-8 (SMU1) 2.0 
 
Cell cycle   
LOC100060949 Arginine vasopressin-induced 1 (AVPI1) 2.1 
LOC100057138 DEAD/H box polypeptide (DDX11) 2.0 
LOC100050857 Retinoblastoma binding protein 8 (RBBP8) 1.8 
LOC100056044 Protein tyrosine phosphatase type IVA (PTP4A2) 1.8 
LOC100060513 Cell cycle associated protein 1 (CAPRIN1) 2.0 
 
Cell death   
LOC100051773 Programmed cell death 2 (PDCD2) 1.9 
 
Ubl conjugation pathway and antiviral defense  
LOC100061587 Zyg-11 homolog B (ZYG11B) 2.1 
LOC100060728 F-box protein 38 (FBXO38) 1.9 
LOC100066866 Ubiquitin-conjugating enzyme E2L 6 (UBE2L6) 1.8 
LOC100062815 ATP-binding cassette, sub-family E (ABCE1) 2.0 
 
Translation   
LOC100064307 Eukaryotic translation initiation factor 3, K (EIF3K) 2.0 
LOC100055350 Eukaryotic translation initiation factor 3, G (EIF3G) 2.3 
 
Others   
LOC100065130 Protein tyrosine phosphatase, liprin alpha 4 (PPFIA4) 8.6 
LOC100065531 Nucleotide binding protein 2 (NUBP2) 3.0 
LOC100065366 RAB6B, member RAS oncogene (RAB6B) 2.5 
LOC100062835 Integrin, beta-like 1 (ITGBL1) 2.3 
LOC100054426 Cadherin 18, type 2 (CDH18) 2.1 
LOC100060652 Scavenger receptor class A (SCARA3) 2.1 
LOC100071763 Rho GTPase activating protein 11A 2.0 
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Table 3.5. Selected down-regulated genes in EIAV wild-type versus EIAV S2- deleted 
infected macrophages classified by Swiss-Prot keyword 
Gene ID Gene name Fold change 
Immune response  
LOC100055841 Phospholipase A2, group VII (PLA2G7) -2.1 
LOC100062762 Cholinergic receptor, nicotinic beta 2 (CHRNB2) -2.3 
LOC100056599 Matrix metallopeptidase 9 (MMP9) -2.5 
LOC100033933 Heat shock protein 90kDa beta (GRP94) -3.2 
LOC100066928 Interleukin 4 induced 1 (IL4I1) -1.9 
 
Transcription regulation and mRNA splicing  
LOC100051444 TGFB-induced factor homeobox 1 (TGIF1) -2.0 
LOC100050136 High-mobility group box 1 (HMGB1) -1.8 
LOC100050121 Small nuclear ribonucleoprotein D3 (SNRPD3) -1.8 
 
Translation  
Human ID 6189 Ribosomal protein S3A (RPS3A)  -2.6 
LOC100071004 Ribosomal protein L27A (RPL27A) -2.3 
LOC100052368 Ribosomal protein S6 (RPS6) -2.0 
LOC100060331 Ribosomal protein L36A (RPL36A) -2.0 
LOC100059235 Ribosomal protein L31 (RPL31) -1.9 
 
Cell death and survival  
LOC100050835 Glutathione peroxidase 1 (GPX1) -2.5 
LOC100055170 BCL2/adenovirus E1B interacting protein like (BNIPL) -1.9 
Human ID 9423 Netrin 1 (NTN1) -2.1 
 
Cell cycle   
LOC100052973 Forkhead box N3 (FOXN3) -1.8 
 
Others   
LOC100060156 Dynamin 3 (DNM3) -3.2 
LOC100050835 Cystatin B (CSTB) -2.5 
LOC100070766 Protein kinase inhibitor gamma (PKIG) -2.1 
Human ID 5569 Protein kinase inhibitor alpha (PKIA) -1.8 
LOC100052644 Ribosomal protein S27 -2.0 
LOC100071944 Ubiquitin protein ligase E3 component n-recognin 4 (UBR4)          -1.8 
   
   
Validation of microarray data 
We selected a number of genes for validation by quantitative real time PCR. PCR 
efficiency for each primer/probe set was determined (Table 3.6). To account for 
differences in PCR efficiencies, the Pfaffl method was used to determine the relative 
expression of the target genes (Pfaffl, 2001).  
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Table 3.6. Validation of TaqMan primer/probe sets and SYBR Green primers 
Target Gene PCR efficiency 
    Mean slope                      %                      R2 
MCP-2* -3.34 99 1 
IL-8 
IL-34 
-3.29 
-3.48 
101 
93 
0.98 
0.99 
RANTES -3.29 101 0.98 
ISG15 -3.15 107 0.99 
MMP-9 -3.21 104 0.99 
CD63 -3.20 105 1 
DNM3 -3.29 101 0.98 
HMG-1 -3.22 104 0.98 
CHMP1B 
18S 
Beta-actin 
-3.29 
-3.57 
-3.28 
101 
90 
101 
1 
0.99 
0.99 
              * TaqMan primer/probe 
 
Although fold changes were similar or slightly greater than what was measured 
by microarray, the direction of gene expression pattern (up or down-regulation) was 
similar (Fig. 3.3).  
Expression of genes encoding proteins involved in the pro-inflammatory 
response, IL-8, MCP-2 and RANTES were validated by RT-PCR (Fig. 3.3). For IL-8 
and MCP-2 there was a statistically significant difference between macrophages infected 
with EIAV17 versus the mock-infected control and also between macrophages infected 
with the S2-deleted virus. In contrast, expression of RANTES was significantly higher in 
the EIAV17 infected cells compared to the mock-infected control but not when compared 
to the mutant virus. Interferon-stimulated gene 15 (ISG15) that is involved in antiviral 
defense and immune response among other functions (Dao and Zhang, 2005), was 
significantly up-regulated in EIAV17 infected macrophages compared with the mock-
infected control and S2-deleted virus infected macrophages. There was a significant 
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difference in gene expression with IL-34, a novel cytokine, in cells infected with the 
wild-type virus compared with the control or with EIAV17∆S2 infected eMDMs. 
 
 
 
Figure 3.3. Validation of microarray results. Showing mRNA expression of selected genes in EMDM 
infected with EIAV17b () or EIAV17bΔS2 (■). Data was analyzed using the Pfaffl method. All values were 
normalized to the endogenous control 18S or b-actin, and represent the log2 mean fold change in 
expression (relative to mock-infected control). Error bars represent ± SEM between three different horses 
(n =3). Student’s t-test was used to determine whether or not significant differences occurred. *, indicates 
p< 0.05.  
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 Interestingly, the EIAV S2-deleted virus did not appear to significantly increase 
IL-34 mRNA expression above the control (Fig. 3.3).  
 Among the down-regulated genes, the array results of all except one, dynamin 3 
(DNM3) were validated by real time PCR (Fig. 3.3). Array data indicated a significant 
down-regulation (3.2 fold) of DNM3 in cells infected with EIAV17 compared with cells 
infected with EIAV17∆S2. However, by quantitative PCR there was not a significant 
difference in the expression levels between EIAV17 and EIAV17∆S2. MMP9, important 
for the migration of immune cells (Jintang et al., 2009), charged multivesicular body 
protein /chromatin modifying protein 1 (CHMP1), involved in modification of chromatin 
structure and endosomal vesicle sorting (Howard et al., 2001) and HMGB1, a chromatin 
associated nuclear factor (Girard, 2007), were found to be significantly down-regulated 
after EIAV infection and significant differences were detected between wild-type virus 
and S2-deleted virus (Fig. 3.3).  CD63, a lysosome protein involved in HIV replication 
in macrophages (Chen et al., 2008) is down-regulated upon EIAV infection and similar 
to the array data, no differences were found between EIAV17 and EIAV17∆S2 infected 
cells. 
Discussion 
Analyses of gene expression profiles are central to the understanding of the 
mechanisms of viral pathogenesis. Until now, there have been no studies addressing the 
global transcription patterns that occur during EIAV infection. In the present study we 
used microarray analysis to examine the response of macrophages upon EIAV infection 
and compared those with macrophages infected with an S2-deleted virus. 
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EIAV infection induced the expression of genes involved in a variety of 
biological processes such as the immune response, transcription, cell cycle, cell survival 
and antiviral defense. Some of the immune response genes found to be differentially 
expressed during EIAV infection were IL-8 and MCP-2. In agreement with our previous 
study, IL-8 and MCP-2 expression were highly up-regulated in eMDM cells following 
EIAV infection and the response was significantly higher with the wild-type virus 
compared with the S2-deleted virus. IL-8 and MCP-2 are major chemoattractants for 
monocytes and macrophages (Lane et al., 2003(Loetscher et al., 1994). Moreover, gene 
expression of RANTES, also a potent chemotactic protein for monocytes and 
macrophages, was highly increased upon EIAV infection (Kuna et al., 1992). These data 
indicate enhancement of the chemokine response is mediated by S2 or by S2 interaction 
with other immune modulators that lead to a more robust wave of monocytes and 
macrophages recruitment to the site of infection, likely contributing to viral 
dissemination and disease progression.  
 Genes involved in cell cycle and proliferation were up-regulated upon EIAV 
infection. One of the genes involved in cell proliferation, IL-34, is a novel cytokine that 
has been shown to stimulate monocyte proliferation and survival, and to promote the 
differentiation of human bone marrow cells into macrophage progenitor cells (Lin et al., 
2008). In a recent report, IL-34 is shown to elicit macrophage proliferation from chicken 
bone marrow cells in culture (Garceau et al., 2010). Validation of the array data 
confirmed the up-regulation of IL-34 in macrophages infected with the highly virulent 
EIAV17 virus relative to the mock-infected control. However, gene expression of IL-34 
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was not affected in macrophages infected with the S2-deleted virus, indicating S2 
specifically plays a role in the induction of IL-34 during EIAV infection. This finding 
suggests that upon EIAV infection, S2 function is to stimulate the production of EIAV 
target cells. Another gene up-regulated during EIAV infection is the G1 to S phase 
transition protein 1 (GSPT-1) also known as eukaryotic release factor 3 (eRF3). eRF3 is 
part of the translation machinery involved in translation termination in eukaryotes 
(Kononenko et al., 2010). Studies have shown that eRF3 depletion induces cell cycle 
arrest at the G1 phase (Chauvin et al., 2007). Up-regulation of eRF3 upon EIAV 
infection may indicate that EIAV favors, at least at the time point studied, the 
progression from G1 to the S phase of the cell cycle.  
It was also interesting to observe up-regulation of the cyclin-dependent kinase 
inhibitor 1A (CDKN1A), also known as p21, during EIAV infection in macrophages. 
p21, is a cell cycle regulator that mediates cell cycle arrest in response to a variety of 
stimuli such as  DNA damage (Johnson and Walker, 1999). Studies have shown that 
inhibition of p21 leads to suppression of HIV replication in macrophages (Vazquez et 
al., 2005). Moreover, p21, is a target for the HIV Vpr accessory protein. One of the 
mechanisms of Vpr mediated cell cycle arrest in the G2/M phase is up-regulation of p21 
expression (Chowdhury et al., 2003). Cell cycle arrest at G2 by Vpr is predicted to play 
an important role in HIV replication and pathogenesis (Yoshizuka et al., 2005). This 
suggests a pivotal role of p21 during the viral replication cycle in macrophages. 
The murine double-minute protein 2 (MDM2) is an E3 ubiquitin ligase that 
inhibits the function of p53 tumor-suppressor protein (Dai et al., 2004). Overexpression 
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of MDM-2 inhibits p53-mediated apoptosis in response to DNA damage as well as p53-
mediated G1 cell cycle arrest (Chen et al., 1996). Cell cycle arrest in the G1/S phase 
leads to the abrogation of a productive infection in macrophages (Schuitemaker et al., 
1994). Moreover, studies have shown that the cell cycle status plays a key role in HIV 
replication (Groschel and Bushman, 2005; Katz et al., 2005). Cells arrested in G2 of the 
cell cycle support HIV replication more efficiently than cells arrested in the G1 phase 
(Goh et al., 1998). Taken together, these results suggest that EIAV modulates expression 
of genes involved in cell cycle progression and inhibition of apoptosis to provide a more 
favorable environment for viral replication. 
Several genes involved in the ubiquitin degradation pathway such as f-box 
protein 38 (FBXO38), baculoviral IAP repeat-containing protein 3 (also known as 
cIAP2), fem-1 homolog b (FEM1B) and ubiquitin-conjugating enzyme E2L6 (UBE2L6) 
were differentially expressed upon EIAV infection. Many viruses are known to utilize 
the ubiquitin-degradation pathway to their advantage, not only by altering the cell cycle 
but also to modulate viral replication and the immune response (Isaacson and Ploegh, 
2009). An interesting example is seen with the HIV Vpu accessory protein. Vpu targets 
CD4 (cell surface glycoprotein present on the surface of T helper lymphocytes) for 
proteasomal degradation through binding to βTrCP, a component of the E3 ubiquitin 
ligase complex. Binding of Vpu to βTrCP leads to CD4 ubiquitination and subsequent 
degradation (Nomaguchi et al., 2008). CD4 down-regulation is required for efficient 
virus replication and infectivity (Hanna et al., 2006). In addition, MDM2, up-regulated 
during EIAV infection, has also been involved in mediating HIV Tat ubiquitination both 
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in vivo and in vitro. Interestingly, MDM2 mediated ubiquitination of Tat, does not target 
Tat for degradation by the proteosome. Instead, ubiquitination positively modules Tat 
transactivation, which is required for efficient replication of HIV (Bres et al., 2003). 
A major group of down-regulated genes during EIAV infection were those 
encoding ribosomal proteins. This observation differs from data previously reported 
during HIV infection. Gene expression analysis of HIV Tat and Vpr expressing cells 
revealed a marked induction of ribosomal genes, suggesting a mechanism by which HIV 
may stimulate viral protein production (de la Fuente et al., 2002; Janket et al., 2004). 
Further studies need to be conducted to determine if a down-regulation of ribosomal 
genes during EIAV infection, specifically at the time point analyzed, correlates with a 
decrease in viral protein synthesis. If a correlation is detected could this be a mechanism 
by which EIAV controls cellular and/or viral protein production to prevent ER overload 
and premature cell death?. In addition to the established roles in protein synthesis, 
several ribosomal proteins have been implicated in extra-ribosomal functions (Warner 
and McIntosh, 2009). For example, the ribosomal protein S3a (RPS3a), a component of 
the small ribosomal 40S subunit, is involved in cell transformation and apoptosis (Naora 
et al., 1998). Moreover, ribosomal protein L34 (RPL34), a component of the 60S 
ribosomal subunit, that is down-regulated upon EIAV infection, is an efficient inhibitor 
of the cyclin D-Cdk4 activity, an important cellular complex for cell progression of the 
G1 phase (Moorthamer and Chaudhuri, 1999).  
Another gene down-regulated during EIAV infection, the high mobility group B1 
protein (HMGB1), is involved in repressing HIV-1 gene expression by causing 
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repression of the LTR-mediated transcription (Naghavi et al., 2003) and acts as a DNA-
binding cytokine, promoting the expression of multiple pro-inflammatory cytokines 
(Andersson et al., 2002).  
Overall these data show that EIAV induces expression of transcription, cell 
cycle, ubiquitin and immune related genes that likely play a role in viral transcription, 
replication and pathogenesis. A down-modulation of translation related genes could be a 
mechanism by which EIAV controls cellular and/or viral protein production to prevent 
ER overload and premature cell death. The role of S2 in macrophage gene dysregulation 
during EIAV infection is not clear. However, the results presented herein identified key 
target genes to continue our studies into the role of S2 in viral replication and disease 
expression in vivo and may aid other investigators in their studies of EIAV pathogenesis. 
Lastly, evaluation of additional time points post EIAV infection will give a more 
complete picture of the global changes in host gene expression that occur during an 
EIAV infection and thereby contribute to our understanding of lentiviral pathogenesis. 
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CHAPTER IV 
IDENTIFICATION OF CELLULAR PROTEINS INTERACTING WITH 
EQUINE INFECTIOUS ANEMIA VIRUS S2 PROTEIN 
 
Overview 
The EIAV S2 gene encodes a 65 amino acid accessory protein of ~7 kDa. 
Although S2 is dispensable for EIAV replication in vitro, it is essential for the 
maintenance of high levels of viral replication and pathogenesis in vivo. Despite its 
essential role in disease expression, the mechanism(s) of S2 action in vivo remain 
elusive. By analogy with other retroviral accessory proteins S2 is likely to exert its 
function by interacting with cellular factor(s). To gain insight into the role of S2 during 
pathogenesis, we sought cellular factors that interact with S2 in a yeast two-hybrid 
screen. In this screen, we identified osteosarcoma amplified 9 (OS-9) and proteasome 
26S ATPase subunit 3 (PSMC3) proteins as interacting partners of S2. These 
interactions were confirmed by co-immunoprecipitation experiments. To our knowledge 
this is the first report regarding S2 interactions with equine cellular proteins, an 
important step to gain understanding of protein-protein interactions that are involved in 
EIAV replication and disease development. Additional evidence is needed to 
demonstrate the physiological relevance of these interactions in vivo.  
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Introduction 
Equine infectious anemia virus (EIAV) is a macrophage-tropic retrovirus (genus 
Lentivirus) of equids. Natural transmission occurs mechanically when biting flies move 
between infected and naïve animals during feeding (Kemen et al., 1978). Upon infection, 
acute disease may develop within days to weeks and is characterized by a high titer 
viremia accompanied by fever and pronounced thrombocytopenia. Clinical outcomes 
depend on the infecting virus strain, as well as host factors; horses frequently survive the 
acute disease episode to become life-long carriers. However some infected animals will 
develop a chronic form of the disease, manifested by recurring febrile episodes with 
clinical symptoms that include lethargy, edema, anemia, weight loss and diarrhea in 
addition to fever and thrombocytopenia (Clements and Payne, 1994; Montelaro et al., 
1993; Payne et al., 2006). 
EIAV genome organization is relatively simple when compared to primate 
lentivirus genomes (Payne et al., 2006). EIAV encodes gag, pol, env, tat and rev genes, 
but few additional auxiliary genes. In fact, EIAV appears to encode only two additional 
proteins, S2 and Ttm, neither of whose functions have been well characterized 
(Fagerness et al., 2006). The approximately 7 kDa (65-68 amino acid) S2 polypeptide is 
encoded by a short open reading frame (ORF) that overlaps env. S2 translation 
presumably occurs by leaky scanning of a tricistronic mRNA encoding Tat, S2 and Env 
or from a bicitronic mRNA encoding S2 and Env (Li et al., 1998; Schiltz et al., 1992).   
The S2 ORF is present in all EIAV strains characterized to date suggesting 
functional significance (Fagerness et al., 2006; Li et al., 2000). Overall the S2 protein 
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has no obvious sequence homology to other viral or host cell proteins (Fagerness et al., 
2006). S2 function has been probed by generating S2 mutant proviruses and assessing 
viral replication in permissive cell lines or in primary monocyte-derived-macrophages 
(Fagerness et al., 2006; Li et al., 2000; Li et al., 1998). Cell culture-based assays suggest 
that S2 does not play a major role in virion production or particle morphology, nor does 
it appear to be packaged into virions, although its presence may subtly enhance viral 
replication (Fagerness et al., 2006; Li et al., 2000; Li et al., 1998; Yoon et al., 2000). In 
contrast to effects observed in cultured cells, S2-deletion has profound effects on 
replication and virulence when assayed in horses or Shetland ponies where S2 is 
required for high titer virus replication and the development of acute disease (Fagerness 
et al., 2006). To gain insight into possible activities of the EIAV S2 protein, we 
performed a yeast 2-hybrid screen to identify host cell proteins that interact with S2. In 
the current report we describe the interaction of EIAV S2 with the cellular proteins 
amplified in osteosarcoma (OS-9) and proteasome 26S ATPase subunit 3 (PSMC3), a 
protein component of the 19S regulatory cap of the 26S proteasome (Hoyle et al., 1997; 
Tanahashi et al., 1998). 
Materials and Methods 
Yeast strain and media 
 The yeast strain used in the two-hybrid study, MaV203, was grown in YPD 
medium (1% yeast extract, 2% peptone, 2% dextrose). Yeast transformants harboring 
both prey and bait plasmids were maintained on synthetic complete (SC) medium 
lacking leucine and tryptophan. Yeast cells were grown at 30 °C. 
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Yeast two-hybrid screen 
 The ProQuestTM Two-Hybrid System with Gateway® Technology (Invitrogen) 
was used to identify potential EIAV S2-interacting proteins. The S2 open reading frame 
was amplified by PCR and was moved into pDESTTM 32 bait plasmid using 
recombination mediated cloning (Gateway® BP Clonase™) according to the 
manufacturer’s instructions. The sequences of the primers used for amplification were 
S2 attB1 forward 5’-GGGGACAAGTTTGTACAAAAAAGCAGCCTTGATGGGAGTATT 
TGGT-3’ and S2 attB2 reverse 5’-GGGGACCACTTTGTACAAGAAAGCTGGGTTTTC 
TTGGTCTCTTGC-3’. The attB recombination sites are italicized and S2 specific 
sequences are indicated (underlined). Recombinants were isolated and subjected to DNA 
sequence analysis to confirm recovery of the desired constructs.  The selected pDEST32-
S2 bait construct was tested for self-activation (in the presence of pEXP-AD502) as 
recommended by the manufacturer. pDEST32-S2 was co-transformed into the yeast 
reporter strain MaV203 (Invitrogen) with a commercially available human spleen cDNA 
library (pPC86 vector, Invitrogen). Transformants were plated onto SC-Leu-Trp (to 
determine the total number of transformants) and the selective media SC-Leu-Trp-His 
+3AT. Patching and replica plating were performed exactly as described by the 
manufacturer to identify transformants that activate the three reporter genes His3, Ura3 
and LacZ. After identification of the possible S2-interactors, both bait and prey plasmids 
were isolated from the yeast and transformed into E. coli followed by selection on LB 
agar with gentamicin and ampicillin respectively. Plasmid minipreps were performed 
followed by DNA sequence analysis. The proteins encoded by the cDNAs were 
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identified by performing BLAST searches.  
ß-gal assay 
 The yeast ß-galactosidase assay kit (Pierce) was used to detect ß -galactosidase 
activity in transformed yeast cells. Briefly, single colonies of yeast transformants were 
diluted in 100 µl of the Y-PER reagent, gently mixing to create a homogenous solution. 
An equal volume of assay buffer was added and the reactions were incubated at 37 °C 
until a color change was observed. Reactions were stopped by adding 100 µl of the 2X ß 
-galactosidase stop solution. 
Generation and expression of tagged fusion proteins  
The EIAV S2 coding sequence was amplified by PCR with primers containing 
restriction sites for BamHI and HindIII. The resulting PCR product was digested with 
BamHI and HindIII and ligated into the similarly digested pET32 vector (Novagen). The 
S2 protein was expressed as a carboxyl-terminal histidine-tag fusion protein in E coli 
BL21 (DE3) cells. To purify S2, the S2-his tagged protein in E coli lysates were added 
to a Ni-agarose affinity column following the manufacturer’s specifications (Invitrogen).  
For expression in mammalian cells, the S2 coding sequence was PCR amplified 
using the forward primer 5’-GAGCTCAAGCTTCGAATTCATGGGATT ATTTG-3’ 
and the reverse primer 5’-ACTGCAGAATTCTCATTTCTTGGTCTCTTG-3’. HindIII 
and EcoRI sites are underlined. The amplified fragments were double-digested with 
HindIII and EcoRI and then cloned into the pEGFP-C2 vector (BD Biosciences). The 
resultant amino-terminal GFP-tagged construct, GFP-S2, was used for transient 
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transfection in Chinese hamster ovary (CHO-K1) cells and expression was confirmed by 
western blot.  
The hOS9, eOS9 and ePSMC3 cDNAs were amplified by PCR and cloned into 
the mammalian expression vector pcDNATM3.2/V5-DEST (Invitrogen) using 
recombination mediated cloning (Gateway® BP Clonase™) according to the 
manufacturer’s instructions. Primer sequences used to generate the mammalian 
expression constructs are as follow: hOS9 attB1 inner forward 5’-
AAAAAGCAGGCTTCACCATGGGTGCTGCACCGCAGGCCAT-3’ and hOS9 attB2 
inner reverse 5’-AGAAAGCTGGGTCAAATTCGTCCAGGTCCCCTGT-3’, eOS9 attB1 
inner forward 5’-AAAAAGCAGGCTTCACCATGGGGTGGACGTATGAATTCTG-3’ 
and eOS9 attB2 reverse 5’-AGAAAGCTGGGTAGAAGTCAAATTCATCCA-3’, 
ePSMC3 attB1 inner forward 5’-AAAAAGCAGGCTTCATGGCGGAGGAGATCATCC-
3’ and ePSMC3 attB2 inner reverse 5’-AGAAAGCTGGGTTGTAGTATTGTAGGTTG-
3’. The attB recombination sites are italicized and gene specific sequences are 
underlined. The adaptor primer sequences, attB1: 5'-GGGGACAAGTTTGTACAAAA 
AAGCAGGCT-3' and attB2 5'-GGGGACCACTTTGTACAAGAAAGCTGGGT-3' 
were subsequently used to add the complete recombination site sequences. Constructs 
were expressed as carboxyl-terminal V5-tagged fusion proteins in CHO-K1 cells. 
Expression of GFP-S2, hOS9-V5, eOS9-V5 and ePSMC3-V5 were confirmed by 
western blot.  
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Western blot analysis and antibodies 
To perform Western blot analysis, SDS-PAGE separated proteins were electro-
transferred onto nitrocellulose membranes. Primary antibodies used in these studies 
were: mouse anti-his monoclonal antibody and mouse anti-V5 monoclonal antibody at a 
1:5000 dilution (Invitrogen). Mouse anti-GFP monoclonal antibody was used at a 1:1000 
dilution (Santa Cruz Biotechnology), mouse anti-human OS-9 (Center for Biomedical 
Invention, University of Texas Southwestern Medical School, Dallas TX) and goat anti-
EIAV S2-his were used at a 1:500 dilution (generated at Bethel Laboratories, Inc).  
Secondary antibodies were horseradish peroxidase conjugates were used at a 1:3000 
dilution (Pierce) and were detected using the ECL Western blotting detection system 
(Amersham). Chemiluminescence was detected by exposure to X-Omat AR film 
(Kodak). 
Far Western blot  
 Purified S2-his and bovine serum albumin (~1 µg) were electrophoresed on 12% 
SDS-PAGE and then transferred onto a nitrocellulose membrane. After the membranes 
were blocked in Tris-buffered saline tween-20 (TBST) containing 5% skim milk for 1 h 
at room temperature, the bound membranes were incubated overnight at 4 ºC with a 
lysate containing the hOS9-V5 protein diluted in TBST.  After washing with TBST to 
remove unbound proteins the membrane was incubated with antibodies against the V5 
tag followed by incubation with HRP-conjugated antibody.  
Cloning equine OS-9 and equine PSMC3 
 Total RNA was prepared from equine monocyte-derived macrophages and cDNA 
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was prepared using SuperScript® II Reverse Transcriptase (Invitrogen) and reverse PCR 
primers.  Initial PCR products were recovered by TOPO TA (Invitrogen). As the equine 
genome sequence was unavailable at the time these studies were initiated, available 
sequences from other species were compared and used to design degenerate primers for 
amplification of equine OS-9 and equine PSMC3 by RT-PCR.  The initial primer set 
used to amplify equine OS-9 was forward primer 5’-ATGGCGGCGGARDCGCTG 
CTGT-3’ and reverse primer 5’-GGGTCAGAAGTCAAAYTCRTCCAGGTCCCCTGT 
-3’). The primer set used to amplify equine PSMC3 was forward primer 5’-
TCCACGGAGGAGATCATC-3’ and reverse primer 5’-CTAGGCGTAGTATTGTAG-
3’.  All PCR reactions were performed using Platinum® Taq DNA Polymerase High 
Fidelity (Invitrogen). The final concentrations of each reagent were 0.2 µM forward and 
reverse primers, 0.2 mM dNTPs, 2 mM MgSO4, 1X High Fidelity PCR buffer, and 1 
unit Platinum® Taq DNA Polymerase High Fidelity. All plasmids were purified using 
QIAprep spin columns (Qiagen).  DNA sequencing reactions were performed using the 
ABI BigDye® Terminator Cycle Sequencing Kit; sequences were generated with an 
ABI PRISM® 3100 Genetic Analyzer. 
Co-immunoprecipitation assays 
Co-immunoprecipitation (Co-IP) analyses were used to confirm the interaction 
between S2 and the interacting proteins identified by the yeast-two hybrid assay. CHO-
K1 cells were transiently cotransfected with GFP-S2 and either hOS9-V5, eOS9-V5 or 
ePSMC3 for 24 h. Cells were washed with PBS and harvested in RIPA buffer containing 
a protease inhibitor cocktail (Pierce). The crude cell lysate was then incubated with the 
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appropriate antibody (anti-V5 or anti-GFP) overnight at 4 ºC on a rotation wheel. Fifty 
µl of agarose G beads (Invitrogen) was used to collect the immunocomplex by gently 
incubation for 2 h at room temperature. The immunocomplex was then washed five 
times with IP wash buffer (Modified Dulbecco’s PBS) and eluted in 100 µl of elution 
buffer (Pierce). Samples were subjected to SDS-PAGE electrophoresis and transferred 
onto nitrocellulose membranes. Western blots were performed using anti-V5 and anti-
GFP antibodies.  
Results 
Identification of cellular proteins interacting with EIAV S2 using the yeast two hybrid 
system 
One of the most commonly used approaches to aid in the understanding of viral 
protein function is the elucidation of interactions between the viral protein and the host 
cell. Analysis of viral-protein interactions is an important step to understand viral 
pathogenesis. Therefore, in an attempt to identify the host cellular proteins involved in 
S2 function, we employed the yeast two-hybrid system to search for S2 binding partners. 
Due to a lack of a validated equine cDNA library for yeast two-hybrid screening, a well-
characterized human spleen cDNA library (Invitrogen) was used in this initial screen. 
Fig. 4.1 shows a schematic representation of the yeast two-hybrid system and the 
expected phenotypes of a positive interaction.  
Briefly, S2 was fused to the Gal4-DNA binding domain “bait” plasmid and 
assayed for interaction with a Gal4 activation domain cDNA library used as the “prey”. 
Both bait plasmid and prey library were cotransformed into the yeast reporter strain 
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MaV203, which contains the HIS3, URA3 and lacZ genes under the control of a GAL4 
promoter. 
 
 
Figure 4.1. The principle of the yeast-two hybrid system. (A) Schematic representation of Gal4-DNA 
binding domain fusion with S2 and the Gal4 activation domain present in the cDNA clones of the human 
spleen cDNA library. (B) Expected phenotypes of a positive interaction. 
 
If bait and prey physically interact with each other, they activate the transcription 
of the three reporter genes. Yeast clones containing interacting proteins grow in histidine 
and uracil deficient medium and activate ß-galactosidase expression. Moreover, an 
additional phenotype can be assayed by the inhibition of growth in media containing 
5FOA (5-fluoroorotic acid) (ProQuest Two Hybrid Sytem, Invitrogen). The strength of 
the interaction can be measure by the activation of two (weak) to four (strong) of the 
reporter genes.  
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The screen resulted in recovery of three cDNAs, encoding two different cellular 
proteins. Fig. 4.2 demonstrates the pattern of reporter gene activation observed for each 
clone and a positive and negative control. Two cDNAs encoding human OS-9 (hOS-9) 
were recovered; both displayed strong interaction phenotypes, activating the three 
reporter genes in the system. One clone (designated LC14.1.1) encodes 430 amino acids 
of hOS-9; the second cDNA (LC10.1) encodes 419 amino acids. These partial cDNAs 
are probably derived from the alternatively spliced isoforms 1 and 2 of hOS-9 shown 
schematically in Fig. 4.3. A cDNA encoding 425 amino acids of the human PSMC3 
(hPSMC3) also was recovered. Co-expression of PSMC3 with EIAV S2 reproducibly 
activated two of three reporter genes in a pattern indicating a weak interaction (Fig. 4.2).  
 
 
Figure 4.2. Summary of yeast two hybrid screen results.  Figure shows a strong interaction phenotype 
for two human OS9 cDNAs and the weak interaction of phenotype of human PMCS3 with EIAVS2 in the 
yeast two-hybrid screen.  Also shown are the interaction phenotypes of two equine OS9 clones. A, is the 
non-interaction control, and E is the strong interaction control. 
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Validation of the yeast-two hybrid screen  
To confirm the results from the yeast-two hybrid screen, we chose to validate the 
strong interaction between hOS-9 and EIAV S2 by performing far-western blot assays, 
using his-tagged EIAV S2 and V5-tagged hOS-9. As shown in Fig. 4.4, interactions 
between hOS-9 and S2 were observed between membrane-bound S2 and soluble hOS-9 
(Fig. 4.4, panel A) and between soluble S2 and membrane-bound OS9 (Fig. 4.4, panel 
B). We also assayed equine macrophage for OS-9 expression and detected an abundantly 
expressed protein of the appropriate molecular weight by western blot using antisera to 
human OS-9 (Fig. 4.4, panel C).  
 
 
 
Figure 4.3. Schematic representation of known OS9 isoforms. Comparison of OS9 isoform 
1 and 2 with cDNAs recovered from the yeast-two hybrid screen. Fragments of equine OS9 
tested in the yeast-two hybrid assay are also shown schematically. 
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Figure 4.4. Far western blot assay results. Panel (A) Far western blots showing the interaction of 
immobilized recombinant S2 with recombinant V5-tagged hOS9 in CHO cell lysates. Lanes 1-3 are reagent 
controls.  Lane 4 shows the binding of V5-OS9 to the membrane at the position of EIAV S2.  OS9 is detected 
using mouse anti-V5. Lanes 5 and 6 show the positions of S2 and the control protein, bovine serum albumin.  
Panel (B) Far western blot showing the interaction of immobilized V5-OS9 with histidine tagged S2 
(bacterially expressed). Panel (C) Western blot using anti human OS9.  Lanes 1 and 2 contain lysates from 
equine monocyte-derived macrophages. Lane 3, CHO-K1 cell lysate. Lane 4, V5-tagged human OS9. 
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Cloning and amino acid sequence comparison of the equine OS9 and PSMC3  
As the complete equine genome sequence was not publicly available at the time 
these studies, initial cDNA clones were obtained using degenerate primers. Partial 
cDNAs of equine OS-9 (eqOS-9) similar to hOS-9 isoforms 1 and 2 were recovered; a 
cDNA indicating a novel splice variant-labeled eOS9 clone_2 was also recovered (Fig. 
4.5). 
 
Figure 4.5. Amino acid sequence comparison of human and equine OS9. * indicates single, fully 
conserved residues (blue), : indicates conservation of strong groups (green) and – indicates no consensus 
sequence (black). 
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Figure 4.5 continued 
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A full-length cDNA encoding the equine homologue of PSMC3 (eqPSMC3) was 
also recovered. The translation of this cDNA reveals strong amino acid sequence 
conservation between human and equine PSMC3 (Fig. 4.6). They differ by only two 
amino acids with conservation of strong groups. 
Figure 4.6. Amino acid sequence comparison of  human and equine PSMC3. * indicates single, fully 
conserved residues (blue), : indicates conservation of strong groups (green) and – indicates no consensus 
sequence (black). 
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Detecting the interaction between S2 and eqOS9 using the yeast two-hybrid system 
  Three eqOS-9 fusions were tested in the yeast 2-hybrid assay. These included 
fragments starting at amino acids 242 and 256 and ending just upstream of the location 
of the alternatively spliced region of hOS-9 (Fig. 4.3). Both of these fragments showed 
strong interacting phenotypes when tested with S2 (Figs. 4.2 and 4.3).  A full-length 
version of the novel eqOS-9 isoform was also tested, but this form failed to interact in 
the yeast 2-hybrid assay suggesting that a region of approximately 40 amino acids (262-
297 of eqOS9) is necessary for the interaction of eOS9 and S2.  
Validation of the interactions by co-immunoprecipitation asssay 
Interaction between EIAV S2 and eqOS-9 was also probed using a co-
immunoprecipitation assay. A full-length version of eqOS-9 clone 14 was fused to the 
V5 tag of pcDNA3.2V5 (Invitrogen). EIAV S2 was expressed as an N-terminal green 
fluorescent protein (GFP) fusion in the pEGFP-C2 vector (BD Biosciences). Plasmids 
expressing eqOS-9 or GFP-S2 were transfected individually into CHO-K1 cells and 
protein expression was verified by western blots using mouse anti-V5 or mouse anti-
GFP antibodies. As shown in Fig. 4.7, panel A, when cell lysates were mixed, specific 
interactions between S2 and eqOS-9 were readily detected by co-immunoprecipitation. 
As the hPSMC3 S2 interaction in the yeast-two hybrid assay was weak, ePSMC3 was 
not rescreened in that assay, but was instead tested for interaction with S2 using the co-
immunoprecipitation assay.   As shown in Fig. 4.7, panel B an interaction between S2 
and eqPSMC3 was readily detected. 
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Figure 4.7. Co-immunoprecipitation of EIAV S2 with eqOS9 and eqPMSC3. Panel (A) 
Co-IP of eqOS9 and S2. Lane 1: Mixed lysates from eqOS9-V5 and GFP-S2 transfected cells. 
Lane 2: Mixed lysates, eqOS9 and GFP-control tranfected cells; immunoprecipitated with 
anti-V5. Lane 3: Mixed lysates, eqOS9 and GFP-S2 transfected cells; immunoprecipitated 
with anti-V5. Blots with anti-GFP or anti-V5 are as indicated. Panel (B) Co-IP of ePSMC3-
V5 and GFP-S2. Lane 1: Lysate from ePSMC3-V5 transfected cells. Lane 2: ePSMC3-V5 
transfected cell lysate mixed with GFP-control lysate; immunoprecipitated with anti-V5. Lane 
3: ePSMC3-V5 transfected cell lysate mixed with GFP-S2 transfected cell lysate.; 
immunoprecipitated with anti-V5. Panel (C) GFP-S2 control. Lysate from GFP-S2 transfected 
cells was immunoprecipitated with anti-V5. Lane 1: Column flow-through. Lane 2. Column 
eluent. Protein markers (L) 
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Discussion 
 While largely dispensable for virus replication in cultured cells, EIAV S2 is 
required for efficient replication and disease expression in infected animals (Fagerness et 
al., 2006; Li et al., 2000). An S2-deleted virus, generated on the background of a highly 
virulent molecular clone, replicates at virus titers two to four logs lower than the parental 
virus in a Shetland pony model (Fagerness et al., 2006). No specific functions have yet 
been ascribed to the 66 amino acid S2 polypeptide and as it shares no overall amino acid 
sequence similarity with any other viral or cellular protein, hence sequence reveals little 
about possible function. To elucidate possible roles of S2 during infection, we sought for 
interacting proteins using a yeast two-hybrid screen against a human spleen cDNA 
library. OS9 and PSMC3 were identified as EIAV S2 interacting proteins.  
 OS-9 is encoded on human chromosome 12q 13-15, a region frequently 
amplified in human cancers (Su et al., 1996). OS-9 is ubiquitously expressed and four 
isoforms have been identified (Bernasconi et al., 2008; Kimura et al., 1998). Both 
cytoplasmic and ER localization of OS-9 have been reported and multiple protein 
activities have been proposed. An early report describes a role for OS-9 in the regulation 
of proteosome-mediated degradation of the transcription factor HIF1-α in an oxygen 
dependent manner (Baek et al., 2005). OS-9 has been reported to bind misfolded 
proteins in the ER lumen, directing them to the endoplasmic reticulum associated protein 
degradation pathway (Alcock and Swanton, 2009). Yet other studies suggest that OS9 
plays a role in protein trafficking by serving as a multi-target adaptor of proteins moving 
from the ER to the Golgi (Jansen et al., 2009; Litovchick et al., 2002; Wang et al., 2007). 
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The various isoforms of OS-9 also may differ in their cellular location and/or function. 
Transport of meprin-β by OS-9 requires isoform 1 but is inhibited by isoform 2 
(Litovchick et al., 2002). In contrast, transport of the dendritic cell-specific 
transmembrane protein (DC-STAMP) from the ER to the cis-golgi occurs in the 
presence of full-length OS9 isoforms 1 and 2, but is inhibited by a C-terminal OS-9 
deletion (Jansen et al., 2009). In this study we report that EIAV S2 interacts with C-
terminal deletions of both isoforms 1 and 2, but does not interact with a novel splice 
variant lacking amino acids 262 to 297. Thus the binding of S2 to OS9 may interrupt 
binding of some cellular OS9 partners, or may influence the trafficking or degradation of 
OS-9 containing complexes.  
 The interaction of EIAV S2 with PMSC3 is notable in that this cellular protein 
was first described as an HIV-1 Tat binding protein (thus its initial designation as Tat 
binding protein 1 or TBP1) (Nelbock et al., 1990). PMSC3/TBP1 is one of 6 ATPases 
found at the base of the 19S regulatory subunit of the proteasome (Tanahashi et al., 
1998). In yeast these ATPases (rpt1-6) do not have redundant functions, as null mutants 
of any single rpt are lethal and cannot be rescued by overexpression of the others (Ferrell 
et al., 2000).  PMSC3/TBP1 is a multifunctional protein involved in diverse cellular 
processes.  For example, cellular levels of the tumor suppressor p14ARF are stabilized 
by PMSC3/TBP1 (Satoh et al., 2009). In contrast TBP-1/PMSC3 promotes degradation 
of hypoxia-inducible factor 1 (HIF-1) (Corn et al., 2003), a master regulator of oxygen 
homeostasis. PMSC3 also has been shown to have a crucial role in regulating the 
transcription of the class II transactivator (CIITA) (Truax et al.). CIITA, a positive 
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regulator of  MHC class II genes is key in the regulation of the adaptive immune 
responses (Krawczyk et al., 2008). A number of other cellular proteins interact with 
PMSC3/TBP1 including tumor necrosis factor receptor associated factors (trafs) 4 and 6 
(Rozan and El-Deiry, 2006).  
It is difficult to predict any specific outcome of interaction between S2 and 
PMSC3/TBP1 as the proteasome itself is multifunctional and regulates many important 
cellular processes directly or indirectly through proteolysis of ubiquitinated and 
nonubiquitinated substrates (reviewed in (Bhaumik and Malik, 2008)). Recently the 19S 
regulatory subunits have been demonstrated to regulate cellular and viral promoters in 
both proteolytic and non-proteolytic modes (Bhaumik and Malik, 2008; Lassot et al., 
2007). During HIV-1 infections, a 19S-like complex was determined to be required, in a 
nonproteolytic manner, for Tat-mediated transcription elongation from the HIV-1 
promoter (Lassot et al., 2007).  
 There is certainly much precedent for roles of lentiviral accessory proteins in 
protein trafficking and degradation. HIV-1 Vpu, Vif and Vpr all induce the 
polyubiquitination and proteasomal degradation of their cellular targets (reviewed in 
(Malim and Emerman, 2008)). HIV-1 Vpu is an accessory protein similar to EIAV S2 
with regard to its position in the lentiviral genome and its expression strategy. Both Vpu 
and S2 are encoded by open reading frames that overlap env and both are expressed via 
leaky ribosome scanning (Krummheuer et al., 2007; Schiltz et al., 1992; Schwartz et al., 
1992). HIV-1 Vpu is an 81 aa protein whose activities include degradation of CD4 and 
interaction with proteasome members to inhibit IκB degradation (Malim and Emerman, 
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2008). Vpu is an integral membrane protein that contains a high proportion of charged 
residues in its cytoplasmic domain and has a pair of serine residues that are 
constitutively phosphorylated by casein kinase II (CKII) (Friborg et al., 1995). While S2 
does not appear to have a transmembrane domain, it does have a myristoylation signal 
such that myristoylated S2 could direct the polypeptide to membranes. S2 also has a pair 
of conserved serine residues that could be substrates for CKII. We cannot rule out that 
the observed S2 interactions with OS9 and/or PSMC3 simply reflect the degradation of 
S2 itself, but given the important roles for other viral accessory proteins in influencing 
key host cell protein levels, this seems unlikely. The results presented herein indicate 
that one role of S2 could be that of altering host cell protein trafficking and/or 
degradation via OS9 and/or PSMC3/TBP1 interactions.  
 Although this is the first report to identify S2 host cellular binding partners, the 
identification of OS9 and PSMC3 as S2 interacting proteins does not provide a clear 
understanding of S2 function. Additional experiments will be needed to further elucidate 
the functional relevance of these interactions in vivo. 
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CHAPTER V 
SUMMARY AND FUTURE DIRECTIONS 
  
In the early 2000s the EIAV accessory protein S2 was found to be a critical 
factor in EIAV infection. S2 is not only necessary for maintaining high levels of viremia 
but also for disease development in the infected horse. A decade later, the mechanism(s) 
by which S2 induces disease remains a mystery. The studies presented in this 
dissertation provide an important starting point to elucidate the mode of action of EIAV 
S2.  
The first study, EIAV S2 enhances pro-inflammatory cytokine and chemokine 
response in infected macrophages, published in Virology (Covaleda et al., 2010), 
addresses the role of S2 in cytokine/chemokine dysregulation. This is the first study to 
delineate the effect of S2 in cytokine and chemokine response during EIAV infection. 
Overall, we determined that S2 enhances the expression of IL-1α, IL-1β, IL-8, MCP-2, 
MIP-1β and IP-10, favoring a pro-inflammatory and chemotactic response. In support of 
this finding, the only anti-inflammatory cytokine evaluated in this study, IL-10, was not 
significantly affected during EIAV infection at the time points analyzed. Our results also 
indicated that S2 is not the sole determinant in cytokine induction, however suggested a 
role of S2 in optimizing a suitable environment for viral replication and dissemination by 
attracting target cells to the site of infection. These results, together with the in vitro 
studies by Lim et al. (2005) that describe a role for EIAV SU in the induction of 
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proinflammatory cytokines in eMDM, and Payne et al. (Payne et al., 2004) and 
Fagerness et al. (2006) that reveal roles of SU and S2 respectively in disease expression 
support the role of pro-inflammatory cytokines in virus replication and disease 
expression in the horse. These results suggest a scenario whereby EIAV SU and S2 act 
in concert to produce a robust pro-inflammatory cytokine response, which attracts target 
cells to the site of infection and promotes vigorous virus replication and disease 
expression.  
Another finding was that S2 specifically up-regulates mRNA levels of IL-34, a 
novel cytokine specifically involved in monocyte proliferation and survival. This 
certainly is intriguing since monocytes/macrophages are the only target cells for EIAV 
infection, unlike HIV. Modulation of IL-34 expression by S2 could increase the pool of 
target cells available for infection greatly influencing disease expression.  
An equine macrophage cell line was not available to use for this project. Thus, 
we used primary macrophage cell cultures to evaluate the cytokine/chemokine response 
upon EIAV infection. Three of the drawbacks with using primary cell lines are (i) 
limited amount of cells that can be obtained at one time from a single horse, (ii) 
activation of isolated cells, and (iii) the high degree of variability in the cytokine 
response among donors. Consequently, we screened for cell activation in each 
experiment to ensure that changes in the cytokine response were due to EIAV infection 
and not to activation of the cells due to manipulations during isolation. In addition, 
although not statistically significant, there were some marked differences in the 
expression of some cytokines and chemokines among donors. For example, IP-10 gene 
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expression at day 4 post-infection varied from 1 to 18 fold between EIAV17 and 
EIAV17∆S2 infected macrophages when examined from different horses. Although 
primary macrophages more closely reflect in vivo effects during EIAV infection, 
established cell lines can provide an unlimited supply of cells, easy standardization, 
reduced risk of cell activation and eliminate inter-donor variability. Recently, an equine 
macrophage cell line was characterized (Fidalgo-Carvalho et al., 2009); the use of this 
cell line will offer the advantage to continue studying several aspects of EIAV infection 
that have been hampered by the lack of a suitable equine macrophage-like cell line. 
As for future studies, as equine immunological reagents become available it will 
be important to determine if the gene expression changes in cytokine and chemokines 
observed during EIAV infection correlate with changes at the protein level. This will 
give a more complete overview of the cytokine response upon EIAV infection.  
To test the hypothesis that S2 enhances monocyte/macrophage chemotaxis 
through up-regulation of IL-8, MCP-2, MIP-1β and IP-10, the following experiments 
can be performed: (1) Measurement of chemokine protein levels in infected supernatants 
by ELISA and (2) Lymphocyte chemotaxis assays to evaluate whether supernatants from 
EIAV infected macrophages enhance lymphocyte chemotaxis compared with 
supernatants from S2-deleted virus.  
In addition, it will be worth testing the extent in which S2 function is in 
regulating the proliferation of macrophage progenitors by increasing the levels of IL-34 
in eMDMs. 
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In the second study, probing the function of the EIAV S2 protein using equine 
whole genome oligonucleotide array, the goals were to identify genes that are regulated 
post-infection and predict cellular processes that are affected during infection of primary 
macrophages with virulent EIAV and compared to those macrophages infected with the 
S2-deleted virus. Microarray analysis revealed a set of differentially expressed genes 
upon EIAV infection. Genes affected by EIAV were involved in the immune response, 
transcription, translation, cell cycle and cell survival.  
Future studies should focus on obtaining a complete picture of gene expression 
profiles upon EIAV infection with additional time points post-infection and evaluating 
the contribution of the genes identified in this study in the pathogenesis of EIAV. 
In the third study, we identified cellular proteins interacting with equine 
infectious anemia virus S2 protein (Accepted for publication April 2010, Virus Res). By 
analogy with other retroviral proteins, S2 is likely to accomplish an essential role in 
EIAV infection by interacting with host cellular factors. Therefore, our goal was to do a 
preliminary search for those factors by using a well-characterized human spleen cDNA 
library available for yeast two-hybrid studies. Here, we report the identification of 
osteosarcoma amplified 9 (OS-9) and proteasome 26S ATPase subunit 3 (PSMC3) 
proteins as interacting partners of S2. We cloned the equine homologs and confirmed the 
interactions by yeast two hybrid and co-immunoprecipitation assays. Both proteins are 
involved in protein trafficking and/or degradation, suggesting a role of S2 in this cellular 
pathway. Although this is the first report to identify S2 binding partners, the relevance of 
these interactions in vivo remains unclear. Additional experiments are needed to 
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demonstrate the physiological importance of these interactions in vivo. One approach is 
to silence OS-9 and/or TBP-1 expression in macrophages and determine the effect in 
viral replication, although since S2 is not required for viral replication in vitro, we may 
not necessarily see a direct effect. Another approach is to map the region where the 
interaction takes place, generate mutant viruses and test those mutants in the animal.  
 In this study, due to a lack of a validated equine cDNA library for yeast two-
hybrid screening, we chose to do an initial search for S2 binding partners using a well 
characterized human cDNA library. However, we are aware that we could have missed 
important S2-interacting proteins due to an undeniable degree of genetic variation 
between humans and equids. Continuing studies to identify more cellular proteins that 
interact with S2 using a custom made equine cDNA library and/or pull-down assays 
combined with mass spectrometry would contribute to discerning the mechanism(s) of 
S2 mode of action.  
Another line of S2 research that will help in the understanding of S2 function is 
the biochemical characterization of S2. As far as we know, no studies have been 
completed in the characterization of the putative motifs in S2. Alignments of available 
S2 proteins sequences indicate several putatively conserved, well-characterized protein 
motifs and therefore are presumed to play an important role in S2 function in vivo. These 
include an N-terminal myristoylation motif (GVTWSA), the nucleoporin motif (GLFG), 
the nuclear localization signal (RRKQETKK) motif, the proline rich (PxxP) SH3 
binding motif, a casein kinase II (CKII) phosphorylation motif and at least two protein 
kinase phosphorylation sites (Leroux et al., 2004; Li et al., 2000). Similar to EIAV S2, 
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HIV Nef is dispensable for viral replication in vitro and is important for achieving high 
viral load and disease progression in vivo (Jamieson et al., 1994; Kestler et al., 1991). 
Studies have shown that the N-terminal myristoylation signal in Nef is essential for 
MHC class I and CD4 down-regulation, which enables HIV to escape from the host 
immune response (Peng and Robert-Guroff, 2001). Moreover, the PxxP motif present in 
Nef, is required for enhanced viral replication, MHC class I down-regulation and disease 
development (Brown et al., 2004; Chang et al., 2001; Khan et al., 1998). Similar to the 
role of the PxxP motif in Nef, it has been hypothesized that the PxxP motif in S2 plays 
also an important role in S2 function in vivo, due the high conservation of this motif in 
all but one of the known EIAV strains and isolates recovered from infected ponies 
during febrile episodes (Craigo et al., 2009; Li et al., 2000; Payne, 2006). Studies need to 
be conducted to determine the role of the different S2 motifs in viral replication and 
disease expression.  
In summary, the results from this study contribute to our understanding of the 
role S2 in disease and allow the formulation of new hypotheses as to the potential 
mechanisms of action of S2 during EIAV infection.  
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